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ABSTRACT
Combination therapy has shown to improve success for cancer treatment. On-
colytic virotherapy is cancer treatment that uses engineered viruses to specifically
infect and kill cancer cells, without harming healthy cells. Immunotherapy boosts the
body’s natural defenses towards cancer. The combination of oncolytic virotherapy
and immunotherapy is explored through deterministic systems of nonlinear differential
equations, constructed to match experimental data for murine melanoma. Mathemat-
ical analysis was done in order to gain insight on the relationship between cancer,
viruses and immune response. One extension of the model focuses on clinical needs,
with the underlying goal to seek optimal treatment regimens; for both frequency
and dose quantity. The models in this work were first used to estimate parameters
from preclinical experimental data, to identify biologically realistic parameter values.
Insight gained from the mathematical analysis in the first model, allowed for numerical
analysis to explore optimal treatment regimens of combination oncolytic virotherapy
and dendritic vaccinations. Permutations accounting for treatment scheduled were
done to find regimens that reduce tumor size. Observations from the produced data
lead to in silico exploration of immune-viral interactions. Results suggest under optimal
settings, combination treatment works better than monotherapy of either type. The
most optimal result suggests treatment over a longer period of time, with fractioned
doses, while reducing the total dendritic vaccination quantity, and maintaining the
maximum virotherapy used in the experimental work.
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Chapter 1
INTRODUCTION
1.1 Conventional Cancer Treatments
The basic principle which underlies cancer treatment is to specifically attack cancer
cells and spare normal cells. Since cancer cells are derived from normal cells, it is a
difficult challenge to select cancer cells, as it is unclear how to separate the differences
therapeutically, aside from many characters specific to cancer cells. Cancer is a com-
plex collection of diseases involving abnormal growth of cells, which tend to proliferate
in an uncontrolled way and in many cases, metastasize. The six main hallmarks of
cancer proposed by Hanahan and Weinberg, include sustained proliferation, evading
growth suppressors, resistance to cell death, enabling replicative immorality, inducing
angiogenesis, and activating invasion and metastasis (Hanahan and Weinberg (2011)).
Treatments have been developed towards disrupting these traits.
Conventional cancer treatments are often accompanied by side effects associated
with unsatisfactory quality of life near time of diagnosis that persists through treatment
and recovery. Many specific cancers are inoperable, and the three modalities: surgery,
chemo- and radiotherapy are given in a variety of combinations, depending on the
situation. In a more general setting, if operable most patients with solid tumors
primarily undergo surgery. Radiation therapy, which uses high energy wave particles
to kill cancer cells and shrink tumors by ionizing the target tissue, is generally
recommended after surgery. Side effects can occur because radiation can also damage
healthy cells and tissues near the treatment area. The effects depend on the form
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of cancer, location doses, and general health of the patient. Effects commonly
include patient fatigue, a decrease in blood count, and skin problems amongst others.
Chemotherapy follows which uses drugs to destroy both cancer and healthy cells,
often resulting in harmful side effects to the patient. Some negative outcomes of
radiation and chemotherapy include toxicity to normal cells and resistance by cancer
cells (Mullen and Tanabe (2002)). Immunotherapy, also referred to as biotherapy,
is a cancer treatment that stimulates certain parts of the immune system to work
harder to attack cancer cells. This process, however, can be quite slow to target
cancer effectively. Targeted therapy is a type of medication that blocks the growth of
cancer cells by interfering with specific targeted molecules needed for carcinogenesis.
With this in mind, every case is unique and includes diverse orders and combinations
of treatments. Therefore, there is still a need to explore more creative anticancer
treatments, including those involving oncolytic virotherapy.
1.2 Oncolytic Virotherapy
Virotherapy is a treatment that uses biotechnology to convert viruses into ther-
apeutic agents by reprogramming viruses to treat diseases. Oncolytic virotherapy
(OVT) can be separated in terms of oncos, “cancer,” lytic, “lysing, bursting or killing,”
and virotherapy; i.e. a virus as a means of therapy that kills cancer. Oncolytic
viruses (OV) have attracted the attention of clinicians, oncologists, experimental-
ists: (Bell and McFadden (2014),Russell et al. (2012),Huang et al. (2010), Breitbach
et al. (2011),Chen et al. (2001),Power et al. (2007),Varghese and Rabkin (2002)])and
mathematical modelers: (Komarova and Wodarz (2014),Tian (2011), Dingli et al.
(2009),Bajzer et al. (2008),Wang et al. (2007),Wodarz (2001)).
2
Viral life cycle
Living organisms are considered having the ability to reproduce, either asexually
or sexually. Viruses are not quite considered living organisms, as they are only able
to replicate themselves by hijacking the genome of their host. The life cycle of viruses
occurs with viral entry, replication, and shedding; respectively. In order to enter the
host cell, proteins found of the surface of the virus interact with proteins of the host
cell. A hole forms in the host cell membrane, which allows the viral particle or its
genetic content to be released into the host cell. This commences viral reproduction.
Assuming the virus has the ability to replicate, it will take control of the host cell’s
replication mechanisms, which allows the virus to make copies of itself. It is possible
the virus can lie dormant within a cell, which can be this lysogenic part of the viral
cycle. Once the virus is reactivated, it will use up the host cells resources and must find
a new host. The process by which viral copies are released to find new hosts is viral
shedding. Viral shedding allows the progeny of viruses to leave the cell by 3 common
ways: budding, exocytosis or apoptosis. For enveloped viruses, budding enables viruses
to it the host cell, which must acquire a host-derived membrane enriched in viral
proteins. Exocytosis is the orioles by which viruses leave the cell, but do not destroy
the host cell. Viral apoptosis is the self-destruction of the host cell while under viral
attack. This is considered the lysis effect from the OV.
Oncolytic virotherapy (OVT) is a targeted therapy that uses engineered viruses to
selectively infect and kill cancer cells. Oncolytic viruses(OVs) can be DNA or RNA,
and wild-type or engineered. Oncolytic viruses have the DNA region that controls
replication, deleted and then modified. Since the replication region is deleted, it is
not possible for the virus to replicate in normal cells, which is a novel feature of OVs.
Genetic or chemical modifications to OVs have been used to selectively target the
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tumor cell surface, de-target sensitive tissues, or can create dual target viruses to
enhance both vascular targeting and tumor infections (Russell et al. (2012)). In the
majority of pre-clinical and clinical trials, OVs not only “die,” but they are “lysed,”
broken down by the virus, producing viral cells that are equipped to attack more
cancer cells. An illustration of how oncolytic viruses encounter normal and cancer
cells is shown in Figure 1.2.
Oncoly'c(virus(
infects(cancer(cell(
Oncoly'c(virus(
infects(normal(cell( No(viral(
(replica'on((
Normal(Cells(
Cancer(Cells(
Healthy(cells((
remain(undamaged(
(
Virus(is(inac'vated((
or(unable(to(
replicate(
Oncoly'c(virus(
Is(able(to(replicate((
In(cancer(cells(
Cancer(cells(rupture(
to(release(progeny(
virus,(which(then(infect(
nearby(cancer(cells(to(
amplify(the(effect(
Figure 1.1: Generalized diagram of the cancer specificity of oncolytic viruses ( Donnelly
et al. (2013)).
OV can directly promote lysis or promote cell death via the immune response.
The next novel feature of OVs is its immunogenicity; the ability of a substance, an
antigen, or an epitope, to stimulate a host immune response. This may be mediated
via innate immune effectors, adaptive antiviral immune responses or adaptive anti
tumor immune responses. There is preclinical and clinical evidence supporting the
importance of immune interactions (Prestwich et al. (2008)). Upon an OV infection, a
change in the pre-existing immunosuppressive microenvironment occurs. After cancer
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cells are infected, they generate “therapeutic” immune responses. These responses,
are stimulated from the antigen message, to help cancer commit suicide (induce
apoptosis). Therefore, the presence of an OV within or near cancer cells, promotes
the immune system to start killing cancer cells. OVs can also be used as vectors to
carry immune-inducing proteins to the cancer site. Thus, the immune system will
start responding to the antigens nearby and attack the cancer. This process can also
assist with eliminating neoplastic cells prior to tumor development, since immune
cells are already at the site of infection where cancer is being produced (Shors (2011)).
These OVs include an inherent form of immunotherapy.
The immune system, plays both ally and enemy when externally or genetically
teamed up with oncolytic viruses. It was originally thought that oncolytic viruses
would just be impaired by the immune system, such that as the virus would spread,
the immune system would work towards liberating the body from the viral burden.
However, the second side to this coin is that the actions from the virus help trigger
a response within the tumor that signal the immune system to attack the effected
environment (Pol et al. (2012)).
Although the idea of oncolytic virotherapy has been around since the mid 1950s,
research was delayed due to inadequate technological availability (Russell et al. (2012)).
Viruses became more understood during the 1950s and 1960s, in parallel with the
advent of cell and tissue culture systems, allowing for ex vivo virus propagation( Kelly
and Russell (2007), Gey et al. (1952)). As technology advanced, the practice of using
viruses therapeutically has fallen hand in hand. In 1991, herpes simplex virus-1 (HSV-
1) with deletion of thymidine kinase UL23 gene, became the first genetically engineered
and replication specific oncolytic virus to be experimentally tested. Adenovirus, with
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E1B 55K gene deletion, named Oncorine, was approved as the worlds first oncolytic
viral therapy, used for head and neck cancer (Toth and Wold (2010)). Now, there
are extended genetic oncolytic viruses being developed as a new class of anti-tumoral
agents towards several solid tumors. Some of the best studied families of oncolytic
viruses are oncolytic herpes simplex virus (oHSV), adenovirus, Newcastle disease virus
(NDV), and vaccinia virus. Recent to this dissertation, oncolytic viruses have been
reinvigorated, as the first oncolytic virus approved for use in the United States by
the US Food and Drug Administration (FDA) occurred on October 27, 2015. This
genetically engineered herpes simplex virus type 1, Talimogene Laherparepvec (T-
VEC), will be used to treat advanced melanoma. T-VEC is designed to replicate within
tumors and produce an immunostimulatory protein called “granulocyte-macrophage
colony-stimulating factor” (GM-CSF) (Ledford (2015)). In short, OV’s are booming
within the evolution of cancer treatments.
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Figure 1.2: Timeline of recent milestones in oncolytic virotherapy. Image modified
from ( Russell et al. (2012))
Combination Therapy
Many cancer treatments use oncolytic virotherapy in combination with other treat-
ments Relph et al. (2016). Viral oncolysis combined with immunotherapy consists
of enhancing tumor killing through adoptive T cellular therapy (transfusion of lym-
phocytes). A common approach of adoptive T cellular therapy is to attach cytokines,
interleukins, and immune stimulatory proteins to the OV, using it as a vector, that
further stimulate the immune system with viral entry. Cytokines, derived from Greek
cyto,“cell” and “kines,” “movement,” are secreted proteins and signal molecules im-
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portant in cell signaling. The term interleukin, inter- “as a means of communication”
and leukin-“deriving from”, is a group of cytokines. Cytokines and interleukins are
commonly attached and expressed with oncolytic viruses to enhance the immune
system towards the cancer site. Immunostimulatory protein, Granulocyte-Macrophage
Colony-Stimulating Factor (GM-CSF) plays diverse roles in cancer therapy. It can
be used either as a monotherapy, or adjuvant to chemo-immunotherapy, adjuvant
with cancer vaccines, GM-CSF expressing oncolytic immunotherapy, and systematic
combination immunotherapy. Cytokines, interleukins, and immunostimulatory factors,
such as GM-CSF, are commonly attached to oncolytic viruses to enhance immune
efficacy.
Another approach is to combine OV with dendritic cell vaccines. Dendritic cell
(DC) based vaccines have potential for cancer immunotherapy, where their use in clini-
cal trials has been performed with patients diagnosed with prostate cancer, melanoma,
lymphoma, and renal cancer (Nesrua et al. (1998), Tjoa et al. (1997), Hsu et al.
(1996), Wierecky et al. (2006)). The main function of DCs are to process antigens and
present it to T lymphocytes in the adaptive immune system. DC’s are professional
antigen-presenting cells (APCs) that have a significant role in the initiation and
regulation of immune responses, as they act as messengers between the innate and the
adaptive immune response. DCs can induce anti-tumor immunity by activating innate
immune cells and tumor-specific lymphocytes that target cancer cells (Zhang et al.
(2011) Kim et al. (2015b)). However, clinical trials have shown an immunosuppressed
microenvironment under tumor influence thoroughly suppresses antitumor immunity
and inhibits vaccine efficacy. This tumor microenvironment (TME) carries several
immunosuppressive mechanisms that impair DC functions and block the development
of anti-tumor immunity, which can lead to decreases in efficacies of immunotherapies
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Rabinovich et al. (2007). There are many efforts towards improving immunother-
apy success via dendritic cells, one of the more promising is the use of oncolytic
virotherapies. Immunosuppression in the tumor microenvironment allows for an
infection-vulnerable environment that can allow viral replication. Subsequently, cancer
cells will be lysed by the viruses. DCs contribute to anti-viral innate immune responses
via activation of innate immune elements, such as NK cells and inflammatory cytokines.
Gene-Based Cancer therapy
Gene therapy is a technique used for the correcting defective genes responsible for
disease development. The two major classes of methods use recombinant viruses and
DNA complexes. Viral vectors are common tools used by molecular biologists to deliver
genetic material into cells. RNA is commonly used to encode a functional, therapeutic
gene to replace a mutated gene. A mutation, is by definition, a permanent change of
the nucleotide sequence of the genome of an organism, virus, extrachromosomal DNA,
or other genetic elements.
Gene-based Immunotherapy
Gene-based immunotherapy is an effective strategy for patients with cancer. The
main cell type that has emerged responsible for initiating and controlling cellular
immune responses are dendritic cells. They are the most powerful antigen-presenting
cell (APC) and potent stimulators of na¨ıve T cells (Srinivasan et al. (2015)).
Adenoviruses are highly effective in gene based cancer therapy for its ability to
efficiently transduce (transfer genetic material from on organism to another) cells,
both dividing and non-dividing (Walsh et al. (2011)). Adenoviral vectors are used in
suicide gene therapy, gene-based immunotherapy, gene replacement strategies and in a
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variety of approaches that combine gene-based therapy with chemotherapy (Srinivasan
et al. (2015)). For the purpose of this dissertation, the oncolytic viruses used are
adenovirus. Oncolytic adenoviruses commonly have E1A deleted, a gene expressed
during adenovirus replication. Adenoviral proteins E1A and E1B inactive proteins,
pRB and p53 in normal cells, respectively. The binding site for the cell cycle related
transcription factor E2F, is an E1A response element. Since E2F is a protein critical
for normal cell cycle regulation and E1A is mutated, the altered adenovirus is unable
to replicate in normal cells (Va¨ha¨-Koskela and Hinkkanen (2014),Veal et al. (1998)).
Safety Considerations
Oncolytic virus do not perform as well as monotherapy. One primary reason is
that for as much engineering there is done to make OV cytotoxic, there is to keep
the OV safe. The treatment of oncolytic virotherapy is considered safe since they
are engineered to cause minimal stress or damage to the body. Adverse genes are
removed and genes that assist with oncolysis are kept or inserted (Patel and Kratzke
(2013)). Furthermore, it has been suggested that dose delivery could be safer when
administered intratumorally. For safety reasons, viral vectors based on vaccinia virus,
adenovirus, reovirus, newcastle-disease virus, coxsackievirus, and herpes simplex virus
have been administered via intramural injection in early phase clinical trials (Shah
et al. (2003), Kaufman et al. (2005), Chiocca et al. (2004), Harrow et al. (2004)).
The molecular basis of tumor selectivity is crucial prior to use in clinical human
studies. Oncolytic viruses must be assayed in vitro for cytotoxicity(lysis) and/or repli-
cation on tumor-permissive and non-permissive cell lines. In many cases, selectivity
is only demonstrated during in-vivo non-clinical studies. Tests are done to search
for altered replication of selective or oncolytic profiles, in order to demonstrate the
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genetic stability of the oncolytic virus.
Toxicity could depend on the route of administration of the oncolytic virus;
therefore, the route and dosing schedule should mimic the intended clinical scenario
as close as possible. Since oncolytic viruses are still incompletely understood, many
questions remain to be addressed in early phase clinical trials. A common strategy used
for oncolytic viral administration is to follow a stepwise approach with intratumoral
injection, then move on to the regional or local administration, and finishing at the
systematic administration.
1.3 Treatment Regimens
Oncolytic virotherapy is currently under investigation for phase I-III clinical
trials for approval for new cancer treatments. The dosing quantity, frequency and
administration could alter the effectiveness of treatments.
Drug Dosing
Cancer therapeutics are generally quite toxic, where the range between achieving
maximum benefit and severe side effects is diminutive. Dose concentrations can be
adjusted to the size of an individual by either drug dose per unit body mass or Body
Surface Area (BSA). Each dose measures the amount of medicine or treatment taken
at one time. Depending on the individual or protocol, doses and frequency vary.
Metronomic Therapy
The goal of most cancer treatments and studies, in vivo or in silico, seem to share
the commonality to eliminate all cancer cells. However, this goal has been proven to be
unrealistic and unnecessary to patient viability (Hahnfeldt et al. (2003)). Aside from
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the dose quantity, the administration regimen plays a large role in cancer treatment
success.
A metronome, used to indicate the exact tempo of music by producing sounds from
a pendulum with an adjustable period of swing, was first examined by Galileo Galilei
around 1602, for timekeeping; it was globally used as the most accurate timekeeping
technology until the 1930s. Perhaps this pendulum could represent a distance that
produces a beat on a homogeneous time distance for inducing cancer treatment.
“Metronomic” dosing allows for regularly spaced dosing. The idea was created to
“resensitize” heterogeneous cell populations to treatments, with intentions to minimize
total tumor burden, rather than complete eradication (Hahnfeldt et al. (2003)). If
feasible, this approach is more practical than complete eradication; maintain a lower
level of cancer instead of cancer elimination. This idea of metronomic therapy is
usually used as metronomic chemotherapy, but in this work, I will introduce the idea
of “Metronomic Oncolytic Viral-Immunotherapy (MOVIT).”
1.4 Motivation and Goals
There is much work to be done in understanding protocol treatments for cancer
patients. More specifically, as OVT is increasingly being used clinically, there are
many questions pertaining to this nature of dosing and scheduling for various OVs for
diverse cancer types. This work investigates dose size and administration scheduling
for oncolytic virotherapy combined with immunotherapy and dendritic cell vaccination.
Since oncolytic virotherapy is still developing, there is much room for mathemat-
ical growth to develop models of cancer treatment questions, synergistically using OVs.
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The research goals are as follows: 1) Develop a mathematical model that can
represent clinical variations for administering oncolytic viral therapy. 2) Parameterize
models using empirical data 3) Shed light on the complex dynamics of combined
oncolytic viral and immunotherapy and 4) Identify optimal treatment strategies (dose
sizes, treatment schedules) for a proposed personalized medicine model.
Chapter 2 presents a literature review of important models representing interactions
between cancer, viruses and the immune system. First, viral dynamic models of
uninfected, infected and free viral variables are discussed. The immune response is
then introduced into the models. The second section introduces models of oncolytic
viral therapy.
Chapter 3 opens the first model created for this work, constructed as an oncolytic
virotherapy model with immune response. Mathematical analysis was performed in
order to gain qualitative insight of the biological dynamics between viruses and cancer
in the presence of the immune system.
Chapter 4 presents the Oncolytic Viral-Immunotherapy (OVIT) model, that ques-
tions the optimal combination of viral and immunotherapy under varying treatment
regimens. This includes altering time of combination use, dose and frequency of
treatments.
Chapter 5 summarizes the results of the research goals of this work and describes
the overall impact from the results. Following the models used in this work, further
models are presented which could have unique mathematical and biological impacts.
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Chapter 2
LITERATURE REVIEW
Beyond clinical and experimental research; mathematical, computational and
in silico models can be quite useful towards the advancements of disease treatments.
In combination with data, carefully developed mathematical models could show subse-
quent stages of an experiment. Furthermore, mathematical models can present the
evolution of how systems interact under ideal, hypothetical and blemished conditions.
Hinged upon relevant biological assumptions and a priori information, mathematical
models provide insight, direction and make predictions that clinical, nor experimental
work would be able to achieve.
Creative approaches at the interface of interdisciplinary fields between mathe-
matics, biology, computational biology, bioengineering and other relevant disciplines,
are essential to improve our understanding of complex biological systems. These
approaches are specifically needed to unravel the oncological complexity involved from
the initiation, progression and metastatic phases of cancer. Mathematical models can
be challenging to develop, since the independent limits of mathematical methods and
biological information tend towards infinity. To start, making the biology a finite
subset from the mass amount of growing information will bring certain mathematical
methods to surface, in a fashion of functions that are not always injective nor surjective.
For science to grow, it is healthy to choose mathematical methods contingent upon
the biological question. Many biological systems can be represented with differential
equations(DEs). For dynamics considering large population sizes, ordinary differential
equations (ODEs) are a suitable tool. Delay differential equations (DDEs) can repre-
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sent the biological role where time delays are hypothesized to be crucial. For questions
pertaining to tumor growth, invasion and angiogenesis, partial differential equations
(PDEs) can be used to represent fluid flow. Stochastic Differential Equations (SDEs)
are used when the state of a variable is not predictable at a given moment in time.
Cellular automata and agent based models are used to represent spatial questions.
Clearly, there are many variants of scientific models representing the biological per-
plexity of cancer. The choice of methods used within these systems can depend on the
quantity of parameters needed, parameters known, biological complexity, interaction
between variables and/or what the question is.
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Basic Cancer Growth Models
Tumor growth models have roots within the works of Ludwig von Bertalanffy
and Benjamin Gompertz. Both produced models of growth, independent of can-
cer, but later applied to cancer. Gompertz published in 1825 his growth model for
“Gompertzian growth” and Von Bertalanffy’s contribution came in 1957. The von
Bertalanffy’s growth model:
M = kW
2
3
where M is the metabolic process, W is the organism’s mass and k is a constant.
Since von Bertalanffly noted that not all processes scale as a 2
3
power of the mass, this
was later replaced with λ and the general relation is:
M = kW λ
where 2
3
≤ λ ≤ 1
Modeling the von Bertalanffy starts with conservation equation: growth equals
“birth”=“death”. In the context of cancer, this equation parallels to “proliferation”-
“apoptosis”. Originally, this process was used for anabolism and catabolism. Then the
growth in mass (W(t)):
W˙ = αW λ − βW µ
Letting α and β be per capita birth and death rates, where λ = µ = 1, yield the
exponential model:
W˙ = (α− β)W
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where α > β leads to exponential growth and α < β leads to exponential decay.
For λ = 1 and µ = 2, this form evolves into the next simple case of modeling
cancer. As a population of cells with potential grow followed by saturation , it is
represented by the logistic ordinary differential equation (Verhulst (1838)):
W˙ = αW − βW 2 = αW
(
1− W
K
)
, W (0)
where W˙ is the time derivative, W = W (t) is the number of cancer cells at time
t, r is the growth rate and K is the carrying capacity, i.e. the maximal size the
population of cells can reach, given the proper nutrients, oxygen, spatial constraints,
etc. The solution of the logistic ODE is a “sigmoidal” curve, exponentially growing in
early stages and then saturating at its maximum.
Instead of a homogeneous population of cancer cells, suppose a population of
heterogeneous cancer cells, i.e., diverse clones, competing with each other and healthy
cells for nutrients, oxygen and space. The growth for cancer can be represented as
follows:
x˙i = rxi − φxi, 0 ≤ i ≤ n, xi(0) = xˆi
where xˆi is the number of cells of type i, with corresponding growth rate ri. With
n cell lines, the competition can be shown with term φ in a variety of ways, such as:
φ =
∑n
i=0 rixi
N
where, N =
∑n
i=0 xˆi in a general case, N representing the total number of cells in
the system, assumed to be constant in this model (Wodarz and Komarova (2005)).
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This is modeled by
˙xi(t) = e
(r−µ)xi(0)
Kareva et al. (2012) showed competition models of over-consumption. Interactions
between consumers and shared resources were modeled. This model introduced a
population of consumes xc as clones, competing for common resources zˆ, which
determines the carrying capacity of the popuation.
x˙c = rxc
(
c− b
∑
A xc
kˆz
)
˙ˆz = γ +
e
zˆ +
∑
A xc
(∑
A
xc(1− c)
)
− dzˆ
where each clones xc is characterized by the values of the parameter c, with contest
per capita birth rate r. The per capita death rate is proportional to
b
∑
A xc
kˆz
, where b
is the rate of resource consumption, and k is the efficacy of resource consumption by
each individual xc and A is the range of possible values of c.
Cancer cells are similar to Lotka-Volterra equations, also referred as predator-prey
systems, in ecology (Lotka (1910),Lotka et al. (1925)). Gatenby and Vincent (2003)
presented the competition model:
x˙ = rxx
(
1− x+ axyy
K
)
y˙ = ryy
(
1− y + ayxx
K
)
where x and y represent population of cancer and healthy cells, respectively, rx, ry,
maximum growth rates, axy, ayx the competition coefficients and carrying capacity, K,
including growth promotion and constraints within the tissue. Competition systems
alike have been a basis for variants of cancer models (Okamoto et al. (2014), Nagy
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(2005), Wodarz (2001), Michelson et al. (1987)).
The models listed above are general principles to illustrate basic phenomena, not
representative of an entire cancer system. These equations are tools to be modified
by incorporating particular properties of a biological system in question, in order to
establish conditions and gain insight of certain cancer dynamics.
2.1 Viral and Immune Models
Viral models are of the infectious disease models base. Infectious disease models
started in the 1766 by Daniel Bernoulli, a trained physician that created a mathematical
model to defend the practice of inoculating against smallpox. Ronald Ross than created
a modern structure for theoretical epidemiology. Kermack and McKendrick published
a simple deterministic model in 1927 (Kermack and McKendrick (1927)). Some
epidemic models were studied through (Hethcote (1976),Miller (1983), Anderson et al.
(1980),Brauer et al. (2001)).
A hearty quantity of mathematical modeling of the immune system were developed
in Los Alamos National Laboratory (Perelson et al. (1976), Perelson and Oster (1979),
Perelson (1989),Farmer et al. (1986), Bell (1970). Dibrov et al. (1977), De Boer et al.
(1990)). This work overlapped into the works of May et al. (1976) and Oster and
PERELSON (1987).
2.2 Viral Dynamic Models
Simple Viral Model
Viral replication in host, was modeled by many, and includes examples from Nowak
and Bangham (1996), who represented populations of uninfected cells, x; infected
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cells, y; and free virus particles, v. These population sizes can either denote the total
abundance in a host, or the abundance in a given volume of blood or tissue.
dx
dt
= λ− dx− βxv, (2.1)
dy
dt
= βxv − ay,
dv
dt
= κy − δv
The susceptible target cell population is produced at a constant rate λ, dies at rate
d and becomes infected by virus at rate β. Infected cells die at rate a and produce
free virus at rate k,with the viral decay rate of δ.
(a) (b)
Figure 2.1: Schematic illustrations of the basic viral dynamics 2.1a. The basic
reproductive number is presented in terms of the burst size, (k
a
) 2.1b. Let u = δ in
the above diagram. Nowak and May (2000)
This model assumes that the cell population is initially uninfected, and a small
amount of viral particles are added. The invading virions manage to infect a number
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of cells, producing new virions, and subsequently infect cells. Two outcomes can
occur when this chain reaction has started: the infesction dies out or it persists. The
outcome depends on the basic reproductive number, R0. Similar to the approach
one takes in epidemiology, this dimensionless ratio is fundamental in discussing the
demography of populations of living things: humans, plants, insects, animals, etc
(Brauer et al. (2001)). Viruses,are considered replicators, rather than forms of life,
which possess genes, evolve by natural selection and replicate by creating multiple
copies of themselves via self-assembly1 (Forterre (2010)). Viruses are not considered
life forms because 1) they are obligate parasites and cannot reproduce on their own,
and 2) have no independent metabolism. For a viral infection, R0, is representative of
the average number of infected cells produced from any one infected cell at the start
of an infection. Figure 2.1b shows a schematic representation of this ratio. The rate
at which one infected cell gives rise to new infected cells is given by βkx
δ
|x= γ
d
, when all
cells are uninfected. Since the lifetime of an infected cell is 1
a
,
R0 =
βγk
adδ
If every infected cell on average produces less than one newly infected cell, R0 < 1,
suggesting the infection will be inviable. With time, the virus will disappear. Other-
wise, for R0 > 1, the infection could expand throughout the population, but there is
no guarantee it will infect the entire population of cells. This model suggests that at
the endemic equilibria, (x∗, y∗, v∗), it is not necessary to evoke an immune response to
achieve a stable equilibrium level of virus in a persistent infection. This equilibria was
found to have limitations: 1) for cytopathic viruses. The Cytopathogenic Effect(CPE)
from virus-structural changes in the host cells that are cause by viral invasion. The
1Molecular self-assembly is the process by which molecules adopt a defined arrangement without
guidance or management from an outside source.
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infecting virus causes lysis of the host cell or when the cell dies without lysis due to an
inability to reproduce (Albrecht T (1996)). The total abundance of cells will be greatly
reduced, and 2)for non-cytopathic viruses, most cells will be infected. The more cyto-
pathic a virus is, i.e.,a >> 0, the smaller the steady state abundance of uninfected cells.
For further classification of the differences between the upcoming models, see
Notion Table 2.1.
Table 2.1: Notational Reference Table
Variable Description
x Uninfected Cells
y Infected Cells
v Free Virus particles
z CTL 2 Cells
Parameter Description
λ Constant production rate
r, d Uninfected cell growth/death rate
β Replication rate of virus
a Infected cell death rate from virus
κ Free virus production rate
δ Viral decay rate
c, b CTL production/decay rate
p death from immunity upon uninfected/infected
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Simple Viral Immune Models
The dynamics of immune responses can be studied to understand the interactions
between abundance of viral and magnitude of the anti-viral immune response. Apart
from functional immune response, which reduce viral load, the correlation between
viral load and immune abundance can be positive or negative. The simplest model
for the interaction between a virus and an immune response will be considered first.
Virions will replicate according to the basic model of viral dynamics (2.1). An immune
response is triggered by encountering a foreign antigen, the tapers off to a constant level
independent of the concentration of virions or infected cells. Cytotoxic T-Lymphocyte
(CTL) cells represent the immune response, for their clear importance of defending
against viral infections.
CTL response
Nowak and May (2000) shows a simple of example of the CTL response in the following
model:
dx
dt
= λ− dx− βxv
dy
dt
= βxv − ay − pyz (2.2)
dv
dt
= ky − δv
dz
dt
= c− bz
In this model, CTL cells are produced at rate c and die at rate bz. It is assumed
c > 0 when y > 0. Otherwise, c = 0. Infected cells are eliminated by the CTL response
a rate pyz. where dz
dt
= cyz − bz represents the nonlinear case, immune response
proportional to the abundance of CTL: and dz
dt
= cy − bz is linear:immune response
2Cytotoxic T-Lymphocyte
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induced at a rate proportional to the abundance of infected cells, but independent of
the CTL abundance
The basic reproductive number, R0 in the presence of CTL cells is:
R0 =
βγk
(a− a1)dδ .
The rate at which infected cells are eliminated by the CTL response at its equilib-
rium level is denoted by, a1 = cp
b
. For models with self-regulating immune responses,
there is always a negative correlation between virus load and abundance of immune
mediators, immune cells, chemokines or antibodies. Patients with weak antiviral
responses have high virus load, as opposed to patients with strong anti-viral response
that have low viral load (Nowak and May (2000)).
2.3 Oncolytic Viral Models with Immune Response
Model Differences Description Citation
dx
dt
= rx
[
1 − (x+y)
K
]
− βxv − ρxy
dy
dt
= βxv − ay
dv
dt
= κy − δv − βxv
f(x, y) = rx
[
1 − (x+y)
K
]
; Assumes untreated tu-
mor growth term, from the Bertalanffy-Richards (BR)
model.
Bajzer et al.
(2008)
h(x, y) = ρxy, cell-to-cell fusion ; g(v, x) = βxv
dx
dt
= rx
(
1 − (x+y)
K
)
− βxv
dy
dt
= βxv − ay
dv
dt
= Nay − δv − βxv
f(x, y) = λx
(
1 − (x+y)
K
)
; Logistic growth; f(v, y) =
Nay ; g(v, x) = βxv
Tian (2011)
Table 2.2: Table of Model differences
The base oncolytic model with immune response was modeled by Wodarz (2001).
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dx
dt
= rx
(
1− x+y
K
)− dx− β xy
dy
dt
= β xy + sy
(
1− x+y
K
)− ay − pvyzv
dz
dt
= cvyzv − bzv
where infected cell proliferation rate sy(1− x+y
K
);Logistic growth of infected cells
Model 2.3 assumes a CTL response occurred at a constant rate, which is not
biologically realistic. The nonlinear CTL response is an immune response proportional
to the abundance of CTL and infected cells, cyz, represented in Table 2.3. Similar to
the previous model, the nonlinear model of the CTL response also leads to a negative
correlation between immune abundance and viral load, if patients differ in their CTL
responsiveness, c. The CTL abundance, z, declines for high values of c. When the
response rate is high, CTLs destroy viral cells, and thus, there are fewer viral cells
to stimulate the immune response, leading to a decrease in z. On the other hand,
for low values of c, the correlation is negative, such that patients with small immune
response have a low CTL response, leading to high viral loads. This model shows
the viral load is, in fact, a better indicator of immune responsiveness, rather the
abundance of immune cells. The linear CTL response in an immune response induced
at a rate proportional to the abundance of infected cells, but independent of the CTL
abundance which gives rise to model 2.3. The main difference in this model is that
the equilibrium viral load does not only depend on the immunological parameters,
which is more realistic (Nowak and May (2000)).
A model with general immune response was used in (Wang et al. (2007)), where
CTL proliferation describes the rate of immune response from virus activation and
p is the actual rate of immune response. Depending on the assumption, the growth
rate of CTL cells, z, from infected cells,y, can have several different representations
in model 2.3. This work explored routes to chaos with increase in time delay, when
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CTL proliferation is cy(t− τ). Periodic solutions were found. It is believed the larger
time delay of immune response and strength of the lytic term can give rise to viral
oscillation in the host (Wang et al. (2007)).
Wodarz (2001) represents a base model consisting of 3 variables uninfected tumor
cells (x), infected tumor cells (y) and virus-specific CTL cells (zv).The model assumes
a quasi steady state for the viral population, including it in the infected class. The
difference here is that logistic growth is assumed for both uninfected and infected
tumor cells. The model assumes upon division of infected cells, the virus is passed
onto both daughter cells.
As the interest of OVT has grown, mathematical models are gradually increasing.
Bajzer et al. (2008) introduced a model for a vaccine strain of measles virus to kill
tumors, shown in Table (2.2) using the Bertalanffy-Richards (BR) growth model
for the untreated tumor growth. The extended death in uninfected cells, ρxy, from
dx
dt
= rx
[
1− (x+y)
K
]
− κxv − ρxy, represents the cell-to-cell fusion with neighboring
cells to form syncytia, which ultimately die. The assumptions in this model were that
syncytia ultimately cause cell death, such that there is a one to one death of each
virus for every uninfected cell. Thus, an elimination term of free virus, βxv, represents
the assumed one-to-one cell death from virus to uninfected cancer cell. The growth
curve data for untreated tumor were fitted (Dingli et al. (2006)) by using Gompertz,
logistic (L) and BR models( Bajzer et al. (1996) ,Byrne (2003), Marusˇic et al. (1994)).
Parameters r, K and  were fit to experimental data for multiple myeloma xenografts
grown in SCID mice (Dingli et al. (2004)) and parameters were estimated using Monte
Carlo simulations. These works suggest weakly cytopathic viruses, i.e. small a cause
more tumor cytoreduction than viruses that destroy cells rapidly.
Table (2.2) includes the model Tian (2011), presentes the replicability of an
oncolytic virus. This model includes the burst size of virions, N , viral compartment
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to compensate for infectious growth rate, and death of virus upon infection, −βxv.
The analysis of this model shows that there are two threshold values of the burst size.
Below the first threshold, the tumor will grow to its maximum carrying capacity, K.
Above this threshold, there is a locally stable positive equilibrium solution appearing
through a transcriptional bifurcation. At or above the second threshold, a family
of Hopf bifurcations arise, as there are one or three groups of periodic solutions.
The study suggests the tumor load can drop to a near undetectable level during the
oscillation or when the burst size is ample Tian (2011).
These base models all suggest the cytotoxic infected cell death rate, a, is of
importance to the abundance of uninfected cancer cells (Bajzer et al. (2008), Tian
(2011), Nowak and Bangham (1996)). Regardless of the changes in the model, they
suggest the burst size , k
a
, or N in (Tian (2011)), will be the contributing factor for
the reduction of uninfected tumor cells.
Modeling Dendritic Cells
There is much literature that captures the dynamics between tumor and immune
system (Kareva et al. (2010), Kareva and Hahnfeldt (2013), Kirschner and Panetta
(1998), de Pillis et al. (2006), de Pillis et al. (2005), Wodarz et al. (1998),Worgall et al.
(1997)).
Dendritic cells are professional antigen presenting cells. Dendritic cell vaccines
have been used with some success in clinical studies of immunotherapy for a variety of
cancers. Portz and Kuang (2013) modeled the efficiency of dendritic cell vaccines when
used in combination with continuous or intermittent androgen deprivation therapy
(Kuang et al. (2016)) .
Kareva and Hahnfeldt (2013) discussed how tumors escape recognition by the
adaptive immune systems. Dendritic cells have shown to switch to glycol’s in an
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activate state. In the tumor microenvironment, however, the DCs activation is often
suppressed, which produces an expansion of immature myeloid cells (MDSCs). The
activation of the adaptive immune response comes from the activity of the innate
immune response. was modeled for (Kareva et al. (2010)). Kareva et al. (2010)
modeled predator-prey dynamics between immune cells: antigen presenting cells,
mature myeloid cells and mature myeloid cells with the prey, as the cancer. Their
results suggest in the absence of treatment and having a weak immune system, cancer
cells grow unrestrained. If the number of cancer cells in the body is low enough,
however, there exists a region where the patient can recover without treatment for
a sufficiently stimulated immune system. This dissertation will investigate how the
immune response and immune system as a means of therapy effect tumor size.
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Chapter 3
MATHEMATICAL ASSESSMENT OF ONCOLYTIC VIROTHERAPY
Oncolytic virotherapy is a targeted therapy that uses engineered viruses to selec-
tively kill and infect cancer cells with the goal to have them eliminated. Deterministic
population models have been considered to represent these interactions (Wodarz
(2001),Wodarz (2003), Wu et al. (2001), Dingli et al. (2006) and Bajzer et al. (2008)).
Replicative adenoviruses have been tested in clinical trials for head and neck cancer
(Nemunaitis et al. (2001)), as well as metastatic colon carcinoma (Reid et al. (2002)).
This work represents the viral-tumor interaction with immune presence, with the goal
to minimize the uninfected cancer cell population, x.
3.1 Model
We have here an ODE system of four variables: the population sizes of uninfected
cancer cells,x; infected cancer cells,y; CTL abundance, z; and free viral particles, v.
The uninfected cancer cells grow logistically at intrinsic rate of increase r, representing
the rate of maximum uninfected tumor cell growth and dies at rate µ. The carrying
capacity of the tumor population, K, including both uninfected and infected tumor
cells, competing for space. Free virus particles infect uninfected cells at a rate
proportional to the product of their abundances, βxv. The rate constant β includes
the effectiveness of this action, which includes the contact rate and probability of
successful infection. Since the model is assuming the virus is passed onto both daughter
cells, the infected tumor cells grow logistically by term sy
(
1− x+y
K
)
, at rate s and are
lysed by the virus at rate, α. The free virions production rate is the burst size, N
times the infected cell mortality rate, αy, assuming cells die when they shed virus.
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The model is shown below:
dx
dt
= rx
(
1− x+ y
K
)
− µx− β xv
dy
dt
= β xv + sy
(
1− x+ y
K
)
− αy − ρyz (3.1)
dz
dt
= σyz − φz
dv
dt
= Nαy − ξv
The nonlinear term σyz is the proliferation of CTL cells in response to viral
antigens and the term ρyz represents the killing of infected cells by CTL cells. In
the absence of antigenic stimulation, CTL cells die at rate φ. The oncolytic virus is
produced at lysing rate α and dies at rate ξ. A description of variables and parameters
used is represented in Table 3.1.
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Table 3.1: Model Description of Variables and Parameters
Variable Description
x Uninfected cancer cells
y Infected cancer cells
z CTL abundance
v Free Viral Particles
Parameter Description
r Maximum uninfected tumor cell growth rate
µ death rate for uninfected cells
K Carrying capacity of overall tumor population
β Viral infectious rate
s Growth rate of infected cancer cells.
ρ CTL response rate
φ immune cell decay rate
N Viral burst size
ξ viral decay rate
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3.2 Analysis
Proposition 3.2.1. (3.1) is positive invariant.
Let ∆ = {(x, y, z, v) : 0 ≤ x+ y ≤ K, 0 ≤ z(t), 0 ≤ v(t)}.
If
(
x0, y0, z0, v0
)
∈ ∆→ ∀t
(
x(t), y(t), z(t), v(t)
)
∈ ∆.
Stability and Existence
The stability of the fixed points can be studies with the eigenvalues in the linearized
system around the fixed points :equilibria with negative real parts are stable, positive
real parts are unstable (Strogatz (2014)).
The system (3.1) has six steady states:
E0 = (0, 0, 0, 0), E1 = (
K(r−µ)
r
, 0, 0, 0), E2 = (0,
K(s−α)
s
, 0, NKα(s−α)
sξ
),
E3 = (0,
φ
σ
, σK(s−α)−sφ
σρK
, φNα
σξ
),
E4 = (
ξ(ξ(αr−µs)−βKNα(s−α))
βNα(βKNα+ξ(r−s)) ,
ξ(βKNα(r−µ)−ξ(αr−µs))
βNα(βKNα+ξ(r−s)) , 0,
βKNα(r−µ)−ξ(αr−µs)
β(βKNα+ξ(r−s)) ),
E5 =
ξ(r(σK−φ))−K(βNαφ+σξµ)
σrξ
, φ
σ
, βKNα[(ξ)(σ(µ−r))−βNαφ(1+ξ(s−r))]−ξ
2[σ(µs−αr)]
σrρξ2
, φNα
σξ
)
For the stability and existence, please refer to Table(3.2)
Theorem 1. In the model (3.1) trivial equilibrium, E0 = (0, 0, 0, 0). E0 is L.A.S
whenever
r < µ, s < α,
otherwise E0 is unstable.
Proof: See Appendix.
Theorem 2. The model (3.1) has boundary equilibrium E1 if and only if r > µ, s < α.
In case of αr − µs > 0, the Viral Free Equilibria (VFE), E1, is locally-asymptotically
stable if and only if R0 < 1 and unstable R0 ≥ 1. In case of αr − µs < 0 E1 is
unstable.
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Proof: See Appendix.
Theorem 3. Let s > α, r < µ. Model (3.1) has complete viral prevalence at E2 is
locally asymptotically stable whenever σ < φs
K(s−α)
Proof:See Appendix.
Theorem 4. Let s > α, r < µ, σ > φs
K(s−α) . Model (3.1) has a boundary equilibrium
point E3 and it is locally asymptotically stable whenever r <
K
K−φ
σ
(µ+ βNαφ
σξ
), otherwise
it is unstable.
Proof: See Appendix.
Table 3.2: Existence Table in the Positive cone
Eq. Point Case I Case II Case III Case IV Case V Case VI
s< α, r < µ s < α, r > µ s > α, r < µ,
σ < φs
K(s−α)
s > α, r < µ,
σ > φs
K(s−α)
s > α, r > µ,
σ > φs
K(s−α)
s > α, r > µ, σ <
φs
K(s−α)
E0
(0,0,0,0)
Exist, Stable Exist, Unsta-
ble
Exist, Unsta-
ble
Exist, Unstable Exist, Unsta-
ble
Exist, Unstable
E1
(x∗,0,0,0)
Not Exist Exist, Stable Not Exist Not Exist Exist, Unsta-
ble
Exist, Unstable
E2
(0,y∗,0,v∗)
Not Exist Not Exist Exist, Stable Exist, Unstable Not Exist Not Exist
E3
(0,y∗,z∗,v∗)
Not Exist Not Exist Not Exist Exist, Unstable Exist, Unsta-
ble
Not Exist
Table 3.2 represents the conditions for any one of the 6 equilibria to exists. Case
descriptions:
When s < α, this represents the growth of the infected cancer cells is less than that of
it’s cytotoxic cell death, also referred as the lysing rate. Therefore, when s < α, E0
and E1 could exist, depending on other conditions. Else, for s > α E2, E3, E4 and E5
could exist.
When r < µ, this represents the growth of the uninfected cancer cells is less than that
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of it’s death rate. Therefore, when r < µ, E0, E2 and E3 could exist. Else, for r > µ,
E1, E4 and E5 could exist
When σ < φs
K(s−α) , the cell response rate is not high enough for the existence of the
CTL population at equilibria. Therefore, when σ < φs
K(s−α) , E0, E1, E2and E4 can
exist. Else, E3 and E5 exist.
The Trivial Equilibrium, E0, exist for all values of the parameters. Biologically, this
condition has little relevance as it is unrealistic all populations will tend to zero.
Further, it we are investigating the growth of cancer, which must allow for r > µ.
Else, for r < µ, the cancer cells would have been dying faster than they would be
growing, which would have prevented the birth of a tumor.
The Virus Free Equilibrium (VFE), E1 has at least one non-zero entity.
E1 = (
K(r−µ)
r
, 0, 0, 0) exist only if and only if r > µ, s < α. Let
R0 =
βNαK
(
1− µ
r
)
ξ
(
α− µ
r
s
)
Further, R0 is L.A.S when β <
rξ
NK(1−µ
r
)
R0, the basic reproductive number, represents the average number of newly infected
cancer cells produced from one viral cell during the treatment period (Brauer et al.
(2001)).
The condition for stability of E2 depends on σ staying below a given threshold.
Biologically, this could represents the suppression, inactivity or delayed immune
response to the viral infection. The first conditions found are where anti-viral CTL
response is established. The condition of this response varies depending if the virus
has obtained 100% prevalence or not.
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3.3 Model Fitting
Experimental design
The majority of clinical trials performing OV have been administered via intratu-
moral injection. Few studies have examined regional or intravenous delivery (Prestwich
et al. (2008)). The data used for this work is from (Huang et al. (2010)). The goal
of the experiment was to use gene-based cytokine treatment as a means of therapy.
There were 8-9 mice in each group, where each subject with B16-F10 subcutaneous
murine melanoma were intratumorally injected with various treatments. First, PBS,
which is a saline, resents the control group with no treatment. The second treatment
was Ad-∆B7, which is a modified adenovirus. The third treatment was Ad-∆B7/IL-12
, the modified adenovirus with the interleukin, IL-12 attached. The fourth was the ade-
novirus expressing IL-12 and a cytokine molecule, 41BBL,Ad-∆B7/4-1BBL. The fifth
treatment was adenovirus expressing both Il-12 and 41BBl, Ad-∆B7/IL-12/4-1BBL.
Mice injected with phosphate-buffered saline (PBS) rapidly formed large tumors, over
3,000 mm3. On day 12, the tumors were large enough that the mice were killed. The
mice with oncolytic Ad treatment were associated with growth inhibition. Twelve
days post treatment, the mean tumor volume for tumors treated with Ad-∆B7, Ad-
∆B7/IL-12 , Ad-∆B7/4-1BBL or Ad-∆B7/IL-12/4-1BBL were 1, 265± 155, 383± 71,
and 136± 22 mm3, respectively showing 60, 88, 89 and 96% tumor growth inhibition
compared to the PBS group.
Parameter Fitting
The model was fit to experimental data from (Huang et al. (2010)) and (Kim et al.
(2015a)) under particular assumptions. The fitting was done in MATLAB using the
nonlinear least squares solver, lsqnonlin. Parameters N, ξ, α,K and φ were estimated
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from prior sources. The oncolytic adenovirus burst size of virions, N = 3500, was used
from an experiment of a prostate specific adenovirus variant (Chen et al. (2001),Kim
et al. (2015a)). The viral decay rate, ξ = 2.3 is used from (Kim et al. (2015a)),
estimated from (Li et al. (2008),Wang et al. (2006)). The lysing rate α = 1, represents
the time for infected cells to undergo lysis on average of once per day, as 90 percent of
viruses exit the tumor site in one day (Worgall et al. (1997)). The carrying capacity,
K = 4000× 106, is estimated as the data is rounded up to the nearest thousandth,
i.e the ceiling of the size of death for mice. CTL death rate, φ = 0.35 was shown in
(De Boer et al. (2001)).
Parameters r, µ, β, s, σ and ρ were fit to experimental data that measured the
overall tumor growth (X+Y) over time during treatment of oncolytic adenovirus. The
data was fit to the following three conditions: i) Phosphate buffered saline (PBS), or
the control group, ii) Ad-∆B7, and iii)Ad-∆B7/IL-12 [Fig 2a, (Huang et al. (2010))].
Two additional experiments were done for the combination of Ad-∆B7/4-1BBL and Ad-
∆B7/IL-12/4-1BBL, but were not fit to (3.1), as its co-stimulatory properties expressed
on antigen presenting cells are not a variable in this model. The initial conditions for
the three data sets were used from the experiment as: (73.7, 0, 0, 0), (59.2, 0, 0, 1010)
and (74.6, 0, 0, 5 ∗ 109). Note, the experiment for Ad-∆B7/IL-12 will display immune
stimulatory effects from IL-12, thus, where T cells are not initially present, their
production is further stimulated.
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Parameter Description PBS Ad-∆B7 Ad-∆B7/IL-
12
r Uninfected tumor cell growth rate 0.43 0.33 0.17
µ uninfected tumor cell death rate 0.0008 0.0008 0.0008
β Viral infectious rate - 1 ∗ 10−13 1 ∗ 10−12
s Infected tumor cell growth rate - [1, 1 ∗ 103] [1, 1 ∗ 102]
σ CTL response rate - - [0.1, 4]
ρ death from CTL cells - - [0.01, 1]
K Carrying capacity 4000 ∗ 106 4000 ∗ 106 4000 ∗ 106
N Burst size of virions - 3500 3500
ξ viral decay rate - 2.3 2.3
α lyse rate - 1 1
φ CTL death rate - - 0.35
Table 3.3: Parameter estimates for model (3.1). The top 6 parameters were fit to data.
The bottom 5 were fixed from previous sources.
Days
0 2 4 6 8 10 12
Un
in
fe
ct
ed
 C
an
ce
r
0
500
1000
1500
2000
2500
3000
3500
Uninfected Cancer cells, PBS
Actual
Predicted
(a)
Days
0 2 4 6 8 10 12 14 16
To
ta
l C
an
ce
r (
m
m
3 )
0
500
1000
1500
2000
2500
3000
3500
4000
Total Cancer cells with AdenoVirus
Actual
Predicted
(b)
Days
0 5 10 15 20 25
To
ta
l C
an
ce
r (
m
m
3 )
0
500
1000
1500
2000
2500
3000
3500
Total Cancer cells with Immune Abundance
Actual
Predicted
(c)
Figure 3.1: Parameter fit to a)PBS data, for r = 0.43, µ = 0.0008. b)Parameter fit to
adenovirus data, r = 0.33, β = 1 ∗ 10−13, s = 1. c) Parameter fit for adenovirus with
immune response; r = 0.17, β = 1 ∗ 10−12, σ = 3.7, ρ = 0.82
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Figure (3.1) represents the parameter fits from experimental data using oncolytic
virotherapy (Huang et al. (2010)). First, the model fit for parameters r and µ compared
from the control group. Those values, were then used as the base to estimate the
values to fit for treatment, r, µ, β, s. The estimates for the treatment fit were used as
the base to estimate the parameters used for treatment in the presence of immune
response, fitting for r, µ, β, s, σ, and ρ. There are three key insensitive parameters:
s, σ and ρ that carry similar numerical dynamics for a range of values. The values
listed in Figure (3.1) were true to the values used in the figure, however, the same
results exist for Fig. (3.1 b) for s = [1, 103] and Fig. (3.1 c) for s = [1, 102], σ = [0.1, 4]
and ρ = [0.01, 1].
Simulations
Substituting parameter values fit to data for initial conditions (74.6∗106, 0, 0, 5∗109).
These values are experimental initial conditions (Huang et al. (2010)).
(a) (b) (c)
Figure 3.2: Sustained oscillations for E4 : β > βc a) Plots all population over the data,
showing sustained oscillation for uninfected and infected cancer cells, as the viral
population oscillates. b) Shows oscillations persist later in time. c) Phase portrait of
sustained oscillations
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(a) (b)
Figure 3.3: a) Viral free equilibria at E1 : β < βc. b) For Z0 = 1, E1 is reached.
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Figure 3.4: Hopf bifurcation diagram of, shown stable to unstable as β increases
We can see in Figure (3.2) that the natural equilibria for these values are E4 =
X∗, Y ∗, 0, V ∗. There are sustained oscillations that appear as β changed threshold
values, which numerically verify the Hopf bifurcation. Extending time to 27 years,4
months and 6 days; or 10,000 days, we can see oscillations continue to occur. At this
point, R0 > 1 since β > βc ; R0 = 6.09, β = 1e− 12, βc = 1.65e− 13. In Figure(3.3),
β < βc, =⇒ R0 < 1. β = 1e − 13, βc = 1.65e − 13 and R0 = 0.6. Note: Figure 3.4
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represents the qualitative behavior of the Hopf bifurcation, however, the quantitative
parameter values were not used here.
Viral reproducibility: Viral reproducibility is the duplication or process of making
a copy of viral cells. We can look at the dynamics of viral reproducibly, by chang-
ing s. In the absence of immune system, at E4 and t = 1000, we can change
s to be on or off, (1,0). The populations to the solutions for the total tumor
size (X+Y)=TumorTot, with Xtot, Ytot, Vtot as the total sizes for uninfected,
infected and viral populations. The total population sizes from s=(1,0) are Tumor-
Tot=(5.42E+08,5.45E+08); Xtot=(4.34E+08,4.35E+08); Ytot=(1.08E+08,1.1E+08)
and Vtot=(1.85E+11,1.87E+11); respectively. Based on the values from model (3.1),
there is little to no change in the overall populations from including the viral replica-
tion. This could suggest that upon viral engineering or viral selecting, under immune
suppression, there is little to no effect whether the virus can self replicate or not. This
is due to the initial viral load being able to be replicated upon the lysing of infected
cells.
3.4 Discussion
This chapter was able to highlight the third goal of this dissertation, to shed
light on the dynamics of continuous oncolytic viraltherapy with immune response.
There are many improvements model (3.1) can benefit from. A major modification
of this model was to incorporate sY
(
1 − (X+Y )
K
)
with viral production term Nαy.
It is not practical that infected growth rate s, can fluctuate with little quantitative
nor qualitative change in overall tumor population. Thus, the condition representing,
sY
(
1− (X+Y )
K
)
must change according to a more detailed understanding of the positive
feedback upon infected cancer cells.
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Absence of immune response could happen for some period of time for oncolytic
viruses that are polymer coated (Cattaneo et al. (2008)). Coating viruses with non-
antigenic polymers is a method of blocking antibody recognition (Green et al. (2004).)
The coated viruses deflect the immune system by being coated with polyethylene
glycol (PEG), which physically blocks the adhesion of proteins that carry foreign
antigens, that are attacked by macrophages. These coats delay the onset of the
immune response, but do not prevent it Phys.org (2013). The nonlinear term σyz
will not have any immune population whenever infected cells are not present. This
is biologically unrealistic; thus, the model needs to include σy to represent immune
response term. This model does not capture the immune stimulation by the OV, and
ought to include an immune response to the uninfected cancer cells, such as ρTxz.
Regarding the burst size, N , previous models suggest the birth size is a contributing
factor to the reduction of uninfected tumor cells (Bajzer et al. (2008), Tian (2011),
Nowak and Bangham (1996)). Based off these works, one could propose that an
increase in N would decrease the uninfected cells. It is important to find biologically
realistic values that support types of replicating viruses with higher burst sizes, and
then incorporate into an extended model. It is suggested that immune response
may affect the parameters determining viral reproduction. CTL mediated lysis may
increase the death rate of infected cells, α. Cytokines released by CD8 or CD4 positive
T cells could reduce the infectivity parameter β and/or the viral production rate, in
this model is α as well (Nowak and May (2000)).
Death rate of uninfected cells, µ can be eliminated, as its value is least sensitive,
small and could be clumped into a maximal growth rate r; r=(growth-death) rate.
Lastly, the impulses of the virotherapy must be introduced via a delta function of the
type u(t) = u0δ(t) + δ(t − 2) + δ(t − 4), for improved parameter fit accuracy. The
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model needs to investigate treatment regimes, with regards to frequency and dosage
quantity.
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Chapter 4
OPTIMIZING COMBINATION ONCOLYTIC VIRAL AND IMMUNO-
THERAPY TREATMENT STRATEGIES WITH A PREDICTIVE MODEL
4.1 Introduction
This chapter investigates dosage regimes for oncolytic virotherapy, combined with
dendritic cell vaccine, in order to address which is the most beneficial to reduce tumor
size, with minimal relapse. After developing these regimes, the most optimal was
implementing into an intermittent schedule regimen. The general goal is to investigate
how sensitive tumor reduction is to combination intermittent oncolytic viral therapy
and immunotherapy. First, this chapter will develop a mathematical model that
can represent clinical variations for administering oncolytic viral therapy. Then the
model will be parameterized using empirical data. The results then identify optimal
treatment strategies for varying dose sizes and treatment schedules, that could be
used towards a proposed model for personalized medicine.
Dendritic cell therapy stimulates anti-tumor responses by causing dendritic cells to
present tumor antigens, such as Tumor-Specific Antigens(TSA) or Tumor-Associated
Antigens (TAA). The immune system is adept at pathogen recognition and provides
receptors specific to pathogen-associated molecular patterns, which included toll-like
receptors (TLR) (Prestwich et al. (2008), Pichlmair and e Sousa (2007)). The innate
immune response can provide an important link to the generation of adaptive immune
responses. Dendritic cells play a critical role in the early immune response. Dendritic
cells are professional antigen presenting cells and are key in innate immune responses,
as they transfer information to the T cells, regarding the identity of foreign antigens.
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A deterministic mathematical model consisting of of 5 differential equations was
developed to predict changes in tumor size in response to virotherapy, immunotherapy
and combinations of both. Various types of oncolytic adenoviruses expressing various
immunostimulatory molecules represent the virotherapy. Mathematical models using
dendritic cell treatments been done by (Kareva et al. (2010), Kuang et al. (2016),
Portz and Kuang (2013)).
To better understand which regimen would be best, a clinical trial table was
produced in order to gain clinical insight to use in the model. The type of cancer is
foremost in order to find which cancers are being treated with oncolytic viraltherapy
on people. The name of the drug and company who owns the name, in order to see
which drugs are beings used on cancers with a name specific to a certain virus. The
phase of the trial can give information pertaining to the quantity of people involved.
The route of administration can have an effect on the viral infectivity rate or maximum
uptake rate of drug. The key focus lies in the quantity of drug, schedule and whither
there is and immune combination. It is important to see the quantities for its count
and order of magnitude of OVs. The schedule of the OV could differ per cancer and/or
virus, thus, ideas for intermittent treatment types could be gathered. Since this work
considers immunotherapy, an option for whither or not immune combination of any
sort was used, is included without bias.
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Cancer
/Stage
O-
Virus
Drug
Name
Company Phase
Trial
R.O.AV
1
R.O.AI
2
QuantityV
(pfu/ml)
Schedule Immune-
Combo
Cite
Melanoma
IIIB-IV
HSV-1 T-
VEC
AMGen III I-LES3
Sub-
CI
4
106
108
108
D1-WK1;
D2-WK4;
DN+/2WKS;
≤ 24 wks; ≤ 48
wks(1 yr/ D1)
≤ 72wks
(18mos from
D1)
Option(OR)
GM-CSF
125µg/m2
14
Days(daily)
Andtbacka
et al.
(2015)
Varied:NSCLC,
Col,Mel,Thy,
Pan,Ova,Gas,
Lei, Mes
Vaccinia
Poxvirus
JX-594
(Pexa-
Vec)
Jennerex I I-VEN 1 ×
105,1 ×
106, 3×
106,1 ×
107,
1.5 ×
107,
3 × 107
*(pfu/kg)
Singe infusion Express:
GM-CSF,
β-gal
Breitbach
et al.
(2011)
Ova, Mes AdenovirusAd5-
D24-
GMCSF
I I-VEN
I-CAV
D1;
8 × 109.
Doses
esca-
late to:
1×1010,
3.6 ×
1010,
1×1011,
2×1011,
2.5 ×
1011,
3 ×
1011,and
4×1011
Single infu-
sion
GM-CSF Cerullo
et al.
(2010)
Liver Can-
cer
Vaccinia
Poxvirus
Pexa-
Vec
Jennerex II I-VEN Low
108;
High
109
Infused low
and high dose
on D1, D15 &
D29
No. In-
serted
GM-CSF
and β Gal
Heo
et al.
(2013)
Gastrointestinal
Carcinoma
AdenovirusOnyx-
015
Onyx
Phar-
maceu-
ticals
II HAI 2×1012 D1,D8 .
Chemother-
apy admin-
istered on
D22
- Reid
et al.
(2002)
Table 4.1: Various clinical trials using OVs to seek treatment types
Table 4.1 was created to gain insight on some key components of using OVTs
clinically. The main focus of this table is expressed in columns Quantity, Schedule
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and Immune-Combo. The clinical variability within these columns could imply there
in not enough suggested OV dose quantity pertaining to a particular schedule, with
or without a source of immunotherapy. Therefore, there are opportunities to explore
the these variations which will be a key motivation within the construction of model
in this work.
4.2 Materials and Methods
4.2.1 Experimental Design
The experiment done by (Zhang et al. (2011)) varied the anti tumor effect of an IL-
12 and GM-CSF co-expressing oncolytic Ad, Ad-∆ B7/IL-12/GMCSF, with dendritic
cells. Ad- ∆ B7 is an oncolytic adenovirus, with mutations in the retinoblastoma
binding sites of E1A and has the E1B binding region deleted, shown in Figure 4.2.
The E1A region has a paradoxical functionality such that they act as oncoproteins
and tumor suppressor proteins, i.e; both stimulating cancer growth and suppressing it
(Frisch and Mymryk (2002)). The creation of Ad-∆ B7/IL-12/GMCSF was generated
by inserting shuttle vectors expressing murine IL-12 and GM-CSF genes into the E1
and E3 regions of the Ad- ∆ B7 viral vector, respectively. Shuttle vectors are vectors
constructed to propagate into two different host species. Thus, DNA inserted into a
shuttle vector can be tested or manipulated in two different cell types (Lodish et al.
(2000)). It has been previously confirmed that Ad-∆B7/IL-12/GMCSF expresses
cancer-specific viral replication and cytotoxicity (Kim et al. (2007)).
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Figure 4.1: The anti tumor activity of IL12 shown. Cytotoxic lymphocytes, CD8+T
cells, natural killer (NK) and NKT cells, are often involved in the mechanism of action
of IL-12 (Trinchieri (2003)).
Dendritic cells were derived from bone marrow cells harvested from cavities of
femurs and tibias of C57BL/6 mice (Zhang et al. (2011)). The dendritic cells were
isolated and grown. Male mice of 6-7 weeks of age, of type C57BL/6, a common
inbred strain of laboratory mice, were injected subcutaneously into the right abdomen
with 5× 105 cultured murine melanoma B16-F10 cells.
When the tumor volumes reached around 120-130 mm3, mice were sorted into
groups with similar tumor volumes. The five treatment groups included phosphate-
buffered saline (PBS) only, as the control, 5 × 109 viral particles/injection of Ad-
∆B7/IL-12/GMCSF only, 1×106 particles/injection of DCs only, combination of 5×109
viral particles/injection of Ad-∆B7/IL-12/GMCSF and 1× 106 particles/injection of
DCs and combination treatment of 5× 1010 viral particles/injection of Ad-∆B7/IL-
12/GMCSF and 1× 106 particles/injection of DCs. The last combination was referred
as the high dose combination therapy. The mice were injected with three doses of
Ad-∆B7/IL-12/GMCSF on days 0-2. For the combination treatment, the mice were
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then injected with three doses of DC’s on days 3-5. The minimum number of mice
per experiment was seven. Tumor growth was monitored every other day. The tumor
volume was calculated with a caliper with the formula volume= 0.523 LW2. Mice
with tumor size > 3,000 mm3 were sacrificed for ethical purposes. Empirical data is
presented in Figure ??.
IL-12 and GM-CSF expression were determined using an ELISA in accordance with
the manufacturers’s instructions. ELISA stands for “enzyme-linked immunosorbent
assay”, a rapid immunochemical test that involves an antibody or antigen (immunologic
molecule). A schematic representation of the genomic stitchers of adenovirus Ad-∆B7
and Ad-∆B7/IL-12/GMCSF is displayed in Figure 4.2. The open star represents the
mutation at the retinoblastoma protein binding site, lacking E1B 19 and ∆E1B; and
∆E3. Murine IL-12 and GM-CSF were inserted into E1 and E3 regions of the Ad-∆B7
genome, respectively (Zhang et al. (2011)). DCs were labeled with CellTracker Red
CMTPX on day 6 of DC culture and harvested on day 8. The tumor-bearing mice
were intramurally injected with 1×106 DCs alone for 3 days or intratumorally injected
with Ad-∆B7/IL-12/GMCSF at 5× 109VP/injection or 5× 1010VP/injection three
time prior to DC injection.
Figure 4.2: Characterization of the oncolytic adenovirus co-expressing interleukin 12
(IL-12) and (GM-CSF)
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Figure 4.3: Data from Figure 2 Zhang et al. (2011) represents the anti tumor effect of
Ad-∆ B7/IL-12/GMCSF in combination with dendritic cells (DCs)
4.2.2 Model Development
With the base model constructed in Chapter 3 and the pre-clinical approaches
used for combination oncolytic and immunotherapy, Model 4.1 is constructed to find
tumor volume changes over different doses, schedules and immune combination.
γ y +κ y( )
yz
K
αy
uv (t)
rx
uD (t)
σ yy
βxv
K
(κ y)xz
K
δzz
Dz
x
yv
δvv
δDD
ρD
N
Figure 4.4: Model schematic. Solid lines depict model flow between compartments.
Dashed lines depict interactions between compartments.
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Uninfected cells grow exponentially at intrinsic growth r, and are destroyed by T
killer (CTL) cells at rate κ. The term κy is dependent on infected cells, as oncolytic
viruses facilitate immune response, here via the T killer cells towards the tumor.
Uninfected cancer cells are infected at rate β, as standard incidence, where carrying
capacity K = x+ y + z +D. Free viral particles are grown from lysing rate α with
burst size N, and decays at rate δv. Viruses have several ways of shedding. The model
assumes viral shedding is done through apoptosis. The mechanisms by which this
happens in the model is via an abundance of viral particles that cause the cell to
explode, releasing viral progeny at rate Nαy and by stimulating the immune to attack
by OV facilitation rates: κy yz
K
and κxyz
K
. T killer cells are activated by dendritic cells
at rate ρ and are deactivated at rate δz. Furthermore, ρ is representing the enhanced
activation/maturation of the dendritic cells via cytokine and interleukin attachments:
GM-CSF and IL-12. Since the model assumes the immune system functions only
in the presence of oncolytic virus, the dendritic population,D, depends on σy, the
infected population. The infected population only exists when there is an oncolytic
virus. Thus, the assumption is the immune response depends on the oncolytic virus.
This is due to the understanding that a tumor microenvironment inhibits the cancer
cells from interacting with immune activation and response signals. The oncolytic viral
immunogenicity trait further enhances the immune response to infected cells, at rate γy.
In Appendix 2, a model constructed in this dissertation included an immune response
term for uninfected cancer cells, γx, which resulted to be insensitive in the model
based off the parameter fit results. Therefore, only γy is included in this simplified, full
model. Dendritic cells decay at rate δD. Therapies are introduced as delta functions for
uv(t) and ud(t) for virotherapy and immunotherapy. The model has fit to experiment
time injections via the delta functions: uv(t) = u0δ(0) + δ(2) + δ(4), and ud(t) =
u0δ(1)+δ(3)+δ(5). This work will alter ui(t) = u0δ(t−ai)+δ(t−bi)+δ(t−ci), i ∈ {v, d},
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corresponding to the schedule of oncolytic viral and dendritic therapy, to investigate
the sensitivity changes on the dynamics.
The equations are as follows:
dx
dt
= rx− βxv
K
− (κy)xz
K
(4.1a)
dy
dt
= β
xv
K
− αy − (γy + κy)yz
K
(4.1b)
dv
dt
= Nαy − δvv + uv(t) (4.1c)
dD
dt
= σyy − δdD + ud(t) (4.1d)
dz
dt
= ρD − δzz (4.1e)
This models variables include x, y, v, z and D representing uninfected cancer cells,
infected cancer cells, virus free particles, T killer cells, and dendritic cells, respectively.
This model was reduced from (Kim et al. (2015a) and Wares et al. (2015)). Model 4.1
has fewer variables and parameters, with intensions to gain pre-clinical and clinical
insights from a simpler approach. The model in Wares et al. (2015) includes an
additional variable, with an equation to represent the antigen buffer between infection
and dendritic cell. The CTL cells from Wares et al. (2015) grow based off antigen
presenting cells, dendritic cells and infected cells. Model 4.1 includes only the den-
dritic cell population for the vaccine count, and CTL cells for the immune attack
onto uninfected and infected cancer cells. Further, Model 4.1 keeps CTL population
only dependent on dendritic cells, which depends on the infected cell population.
Additionally, Model 4.1 accounts for additional immune attack on the infected cell
populations due to the nature of the oncolytic virus enhanced immune stimulation
trait, −γyy. The delta functions used here in Model 4.1, uv(t) and ud(t), are not
limited to 6 days, as in Wares et al. (2015). Also,Wares et al. (2015) used only 3
quantities of each treatment, but Model 4.1 accommodates for extended time functions,
depending upon dose limiting conditions.
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4.2.3 Parameterization
Model (4.1) was fit to experimental data from Zhang et al. (2011). The fitting was
done in MATLAB 2014b using the Levenberg-Marquardt algorithm with nonlinear
least squares solver, lsqnonlin. The solver was ode23.
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Parameter Description PBS Ad-∆B7/
IL12/ GMCSF
Ad-∆B7/IL12/
GMCSF +DC
Ad-∆B7/IL12/
GMCSFH +DC
r Uninfected tumor
cell growth rate
0.385 0.385 0.385 0.385
γy T cell contact rate
via IL-12, infected
- 0.5 1 1
σy innate dendritic ac-
tivation response
from infected cells
- 1.2 1.5 0.9
β Viral infectious
rate
- 2.588× 10−4 7.5703× 10−4 3.12× 10−5
κ T cell killing rate
facilitated by OV
- 5× 10−5 7× 10−5 1.5× 10−3
ρ adaptive T cell acti-
vation rate by den-
dritic cells via GM-
CSF
- 10 0.8 1
δz T cell decay rate - 0.35 0.35 0.35
δD Dendritic cell
death rate
- 0.35 0.35 0.35
u0V Adenovirus concen-
tration
- 5× 109 5× 109 5× 1010
u0D Dendritic concen-
tration
- - 1× 106 1× 106
N adenovirus burst
size
- - 3500 3500
α Infected lysis - - 1 1
δV Viral decay rate - - 2.3 2.3
Table 4.2: Parameter estimates for Model (4.1). Values obtained using nonlinear least
squares, lsqnonlin, to fit the model to empirical data from Zhang et al. (2011).
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Parameter estimates were obtained for six parameters, as seven were estimated
from previous literature, described from (4.1). The exception is ρ, as we allow ρ to
be fit here. ρ represents the T cell activation rate by dendritic cells; therefore, it will
represent the effect of GMCSF and IL-12. The experiment done in Zhang et al. (2011)
varied the anti tumor effect of an IL-12 and GM-CSF co-expressing oncolytic Ad,
Ad-∆ B7/IL-12/GMCSF, with dendritic cells.
One is required to sacrifice a mouse with tumor size greater than 3,000 mm3. The
data points represent the mean ± standard error for the combined tumor sizes of the
mice shown in Figure??. The control group of PBS only allowed for aggressive growth
of melanoma, rapidly forming large tumors by the 8th day of treatment, reaching
over 2,500 mm3. Mice treated with DC’s or Ad-∆ B7/IL-12/GMCSF alone, showed
substantial inhibition of tumor growth. More specifically, the treatment optional that
demonstrated the maximum tumor reduction was the combination of dendritic cell
vaccine with high concentration oncolytic virotherapy.
As the model assumes the immune system reacts to the presence of the oncolytic
virus, all data sets were used to parameter fit except the data for Dendritic cells (ii),
as there is no viral therapy involved nor parameter to fit. The top six parameters
estimated in Table 4.2 were fit to the data sets. To start, the growth term r, was fit
to the PBS data set, setting all other parameter values to 0. Since there was virus
and immune response in the remaining sets, all of the parameters were fit to the data.
The values fit for data Ad-∆ B7/IL-12/GMCSF were used as a base to estimate the
subsequent experimental data in a hierarchical fashion.
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Figure 4.5: Model (4.1) fits to data sets of Zhang et al. (2011)
4.3 Results
The Levenberg-Marquardt algorithm was used since the problem is undetermined,
since the model was constructed with fewer equations than dimensions. The limitations
of the Levenberg-Marquardt algorithm is that is does not handle bound constraints.
These strength of this algorithm is it is the algorithm that suits the number and
equations and dimensions of the model, due to the complexity. The weakness of not
having bound limits on the parameters values is that the range base selection is based
off literature, or previous fits from simpler models.
Using the parameter fits from Section 4.2, relevant modeling questions are now
considered. 1) Are there better treatment regimens that reduce overall tumor size
by day 30? Since the fits include up to day 30, end tumor volume at day 30 can be
compared for a variety of regimens. 2) Can metronomic treatment further reduce
overall tumor size? Once regimens are considered over the initial 6 days, the model can
extend the time to compare end tumor volume. 3) How do the effects of intermittent
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combination oncolytic viraltherapy and immunotherapy reduce overall tumor size?
Once optimal regimens are found for short and longer treatments, these treatments
can be considered one sequence, administered intermittently over extended period of
time.
When administering combination treatment, order does matter; therefore, this
section will cover a variety of permutations for combining oncolytic virotherapy and
dendritic therapy. Included are data generated from permutations of possible treat-
ment regimens under varying administration conditions to show the overall tumor size.
All data and figures were generated in Matlab2014.
4.3.1 Dose Regimen
A dosage regimen is the schedule of doses of a therapeutic agent over time. This
includes the time between doses, the time when the doses are to be administered, and
the quantity of treatment to be given at each specific time.
It will be assumed that any treatment is a permutation of OV, DC and/or days
off. Note: For Sections 4.3.1-4.3.2, all permutation calculations were simulated over
30 days; the Tumor Volume presented is on day 30. This was to match the overall
treatment done experimentally. Section 4.3.3 allows for further time and will be
discussed then.
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Regimen End Tumor Volume mm3
DVVVDD 49
DDDVVV 50.3
DDVDVV 53.1
DDVVVD 55.9
DDVVDV 56.7
DVDDVV 58.4
DVDVDV 62.3
DVDVVD 62.7
DVVDDV 64.6
DVVDVD 65.9
VDDDVV 77.4
VDDVDV 86.7
VDDVVD 94.2
VDVVDD 98.6
VDVDDV 101.2
VDVDVD 113.6
VVDDDV 146.3
VVDDVD 181.9
VVDVDD 209.3
VVVDDD 630.7
Table 4.3: Exactly 3 oncolytic viruses and 3 dendritic cell vaccines as treatment
strategy. The above table represents all 20 permutations that predict the tumor size
at day 30. Each injection included V=5× 1010, D=1× 106.
This work will assumes the maximum viral and dendritic dosage is parallel to the
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optimal experimental dosages used in Zhang et al. (2011), for the experiment regimen.
Since there are three doses for each treatment of V at 5× 1010 and D at 1× 106, the
maximum dose per treatment is Vmax = 1.5× 1011 and Dmax = 3× 106. In Sections
(4.3.1-4.3.4), maximum dosage will vary and will be represented by VTot and DTot.
Figure 4.6: Represents the top 3 in each group starting with Dendritic Vaccination
and Oncolytic Virotherapy corresponding to Table 4.3
Figure(4.6) shows the top best treatment’s for altering the administration of OV
and DC treatments, maintaining a maximum of 3 and 3 for each treatment type.
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Permutations of V and D with Flexible Frequency
Permutation Day End Tumor Volume Oncolytic Virus Dendritic Cells
Rank 1 2 3 4 5 6 (mm3) dose number dose number
1 V V V V V V 4.3 6 0
2 D V V V V V 6.4 5 1
3 V D V V V V 13.6 5 1
4 V V V V V D 14 5 1
5 D V V V V D 17.9 4 2
6 D D V V V V 22 4 2
7 V V D V V V 22.1 5 1
8 V V V V D V 22.8 5 1
9 D V V V D V 24 4 2
10 D V D V V V 25.2 4 2
11 D V V D V V 27.3 4 2
12 V V V D V V 29.2 5 1
13 V D V V V D 35 4 2
14 V D D V V V 35.7 4 2
15 V D V V D V 40 4 2
16 V D V D V V 40.9 4 2
17 D V V V D D 49 3 3
18 V V V V D D 49.6 4 2
19 D D D V V V 50.3 3 3
20 D D V D V V 53.1 3 3
Table 4.4: Permutation table representing flexible count for oncolytic viruses and
dendritic cell vaccines, over 6 days. 20 permutations of the 64 are displayed, that
predict the tumor size at day 30. Each injection included V=5× 1010, D=1× 106.
Table (4.4) represents all possible 64 permutations of six treatments for the first
six days of therapy. The data is sorted from treatment permutations predicting the
lowest tumor size through highest tumor size over 30 days. Since each dose of V is
5× 1010 (VP) and D is 1× 106 (DC), these permutations allow for [0 ≤ V ≤ 3× 1011]
and [0 ≤ D ≤ 6× 1010]. The regimen leading to the lowest tumor volume over the
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experimental time frame predicts to administer oncolytic virotherapy for six days in
a row at 5× 1010 (VP), i.e Vmax = 3× 1011, with a total tumor volume of 4.3 mm3.
The worst scenario was administering dendritic vaccine daily for six days, predicting
tumor size of 1.1861 × 107 mm3. Based on these permutations from the model, a
large tumor, such as results from D-D-D-D-D-D-D, is not optimal, but the scenario of
V-V-V-V-V-V-V with a drastic tumor reduction may also have unfeasible implications.
Although this could represent tumor remission, we take into account that this may
also include high cytotoxicity of VPs in the subject.
Figure 4.7: Represents the top 2 regimens of non-restricted therapy for Dendritic
Vaccination and Oncolytic Virotherapy corresponding to Table 4.4
Assuming the initial maximum dose administered for the experiment done in Zhang
et al. (2011), we can look into the permutations of altering dendritic cell injections at
1× 106 and oncolytic virotherapy at 5× 1010 as will be shown in Section 4.3.2
4.3.2 Maximum Tolerated Dose
The goal of the maximum tolerated dose (MTD) applied to cancer is to generate
the highest level of cancer cell mortality without causing unacceptable side effects.
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Assuming there is a maximum tolerated dose for the patient, it is important to search
for an altered schedule that keeps the total dose bounded, but allows frequency and
order to vary.
Permutation Day End Tumor Volume Oncolytic Virus Dendritic Cells
Rank 1 2 3 4 5 6 (mm3) dose number dose number
1 D V V V V D 42.9 4 2
2 V V V V V V 44.1 6 0
3 D V V V D D 49 3 3
4 D D D V V V 50.3 3 3
5 D D V V V V 50.3 4 2
6 D V V V V V 51.9 5 1
7 D D V D V V 53.1 3 3
8 D V V V D V 54.2 4 2
9 D D V V V D 55.9 3 3
10 D D D D V V 56.2 2 4
11 D V D V V V 56.5 4 2
12 D D V V D V 56.7 3 3
13 D D D V D V 57.6 2 4
14 D V D D V V 58.4 3 3
15 D V V D V V 59.7 4 2
16 D D V D D V 61 2 4
17 D V D V D V 62.3 3 3
18 D V D V V D 62.7 3 3
19 D V V D D V 64.6 3 3
20 D V V D V D 65.9 3 3
Table 4.5: Permutation table of limited maximum doses for oncolytic viruses and
dendritic cell vaccines. 20 permutations of the 64 are displayed, that predict the tumor
size at day 30. Vmax = 1.5× 1011, Dmax = 3× 106, where the dosages were fractioned
over 6 days.
Table (4.5) shows the options for administering combination treatment without
limitations on frequency per treatment; however the maximum dosage concentration
is limited to the amount used in the experiment from (Zhang et al. (2011)). This
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modeling approach allows for a varied number of base values for a given order of
magnitude. The theory behind optimal control, however, would suggest a specific
optimal value for a dose and frequency, which could be infeasible. It could be useful in
future work for a very specific dose or frequency condition, without as many constraints
on the model.
(a) (b)
Figure 4.8: 6 days of altered treatment, limited to maximum OV and DC dose
corresponding to Table 4.5
In Figure(4.8), the top 4 are plotted from the 64 permutations listed in Table
(4.5) in an ascending order in the legend. Figure(4.8a) compares the most optimal
of all 6 limited doses at DVVVVD and VVVVVVV. Although the total tumor size
is 42.9 mm3 and 44.1 mm3, respectively, we can see slight peak differences early
on. It seems that having some dendritic build up before oncolytic treatment, can
prime the immune system. Furthermore, the presence of the oncolytic virus redirects
the immune response to the tumor site and/or through the potentially restricted
tumor microenvironment. This could justify why the peak is lower for simulations of
initial administration of dendritic vaccine followed by oncolytic virotherapy. Fig4.8b
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compares the third and fourth optimal regimen of the 64 permutations, from top to
bottom. Continuing the idea of optimal treatment of dendritic vaccination followed
by oncolytic virus, DVVVVDD has a lower peak and slightly smaller tumor size than
DDDVVV.
Rest Days
Having rest days during treatment is commonly done to allow the body to recover. This
also may entail increased doses of treatment on one particular day, rather than what
would be administered on a more dense dosing scheduled. This section investigates
the inclusion of rest days during treatment.
63
Permutation Day Tumor Volume Oncolytic Virus Dendritic Cells Rest Day
Rank 1 2 3 4 5 6 (mm3) dose number dose number count
1 V - V - - V 26.6 3 0 3
2 V V - V - V 27.7 4 0 2
3 V V V - - V 29.7 4 0 2
4 V V V - V V 33.8 5 0 1
5 V V - - - V 34.1 3 0 3
6 V V V V - V 37 5 0 1
7 V - V V - V 37.8 4 0 2
8 D V - V V D 37.9 3 2 1
9 D - V - V V 39.5 3 1 2
10 D - - V - V 39.6 2 1 3
11 D V - - V V 39.9 3 1 2
12 D - V - - V 40.1 2 1 3
13 D - - V V V 40.3 3 1 2
14 V V - - V V 40.5 4 0 2
15 D - V V V D 40.9 3 2 1
16 D V - - - V 41.3 2 1 3
17 D - V - V D 41.5 2 2 2
18 V V - V V V 41.5 5 0 1
19 D - - - V V 41.8 2 1 3
20 D V - - V D 41.8 2 2 2
Table 4.6: Permutation table representing flexible count for oncolytic viruses and
dendritic cell vaccines, allowing for rest days. 20 permutations of the 729 are displayed,
that predict the tumor size at day 30. Injection quantities: Vmax = 1.5 × 1011,
Dmax = 3× 106, where the dosages were fractioned over 6 days
Table(4.6) represents keeping the schedule of six days fixed, but allowing for off
days of treatments. The maximum dosage for OV and DC are the same over 6 days as
used in Zhang et al. (2011), but divided out accordingly. This also could suggest that
some days may have higher doses per day than the initial dose per original treatment
quantity, but would be administered less frequently of the treatment time frame.
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Figure 4.9: Top simulations from Table 4.6
These results have caused some question in the use of combination treatment. It
appears that the optimal outcome of including treatment over rest days shown in
Table 4.6 is V-V- -V at tumor volume at 26.6 mm3. Interestingly enough, the 39th
permutation rank from Table 4.5 is VDVDDV at tumor volume at 101.2 mm3. It
seems that the same sequence of V at dose 5× 1010 with rest days did better than
that of substituting dendritic treatment within those rest days.
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Table, Permutation Day Tumor
Volume
Oncolytic
Virus
Dendritic
Cells
Total
Rank Rank 1 2 3 4 5 6 (mm3) dose number dose number OV dose
[4.6], 1 1 V - V - - V 26.6 3 0 1.5× 1011
[4.5], 39 2 V D V D D V 101.2 3 3 1.5× 1011
Table 4.7: OV in the same sequence as off days as of dendritic vaccination does better alone.
Tumor volume predicted at day 30. Vmax = 1.5× 1011, Dmax = 3× 106
We can see here that oncolytic monotherapy performs better than combination of
viral and immunotherapy. In fact, the top 7 of the top 20 of the 64 permutations of
V and D with rest days at limited maximum dose listed in Table (4.6), only include
oncolytic virus. As mentioned earlier, the model makes the assumption that the cancer
is in an aggressive stage where the tumor microenvironment does not allow for the
immune system to naturally attack the uninflected cancer cells. Only infected cancer
cells are subject to immune attack due to the oncolytic viral immunogenic traits
induced in the cancer cells. Thus, under excessive dendritic vaccination, the immune
system annihilates the infected cancer cells quickly. A majority of the infected cancer
cells undergo cell lyses, releasing virions which can reinfect cancer cells and re-stimulate
the immune system to attack both uninfected and infected cancer populations at rate
κy. If the infected cells,y, are removed too quickly, the immune system cannot kill
the uninfected cancer cells and thus, the cancer will continue to grow. Due to the
inhibition of the infected cells from the dendritic cells, Table (4.7) includes the regimen
in rank 2, represent the dendritic vaccination attack and kill infected cells rapidly; the
effect from the oncolytic virus will be reduced since its progeny cells are not present,
allowing for cancer to grow further. In Section (4.3.2), we look into optimal regimens
lowering the total dendritic concentration from 3× 106 to 3× 105.
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Maximum Tolerated Dose with Rest Days with limited DC
“Less is more”, as the saying goes, applies to the models results, as excessive dendritic
vaccination in several regimens is not only less effective, but can increase tumor
growth. In Section 4.3.1, we’ve assumed the optimal dose for oncolytic virotherapy is
5×1010(VP)/dose and 3×106 (DC)/dose based off the concentration values used in the
experimental work of Zhang et al. (2011) for Ad-∆B7/IL12/ GMCSFH +DC in Table
[4.2]. The dose ranges have been [0 ≤ V ≤ 1.5× 1011] and [0 ≤ D ≤ 3× 106]. Suppose
DmaxL < Dmax. We can conjecture that there will be enough dendritic vaccination
to boost the immune response to kill uninfected and infected cancer cells, but not
so excessive that it will kill off the infected cells. Table [4.8] represents therapy with
Vmax = 1.5× 1011 and DmaxL = 3× 105.
67
Permutation Day End Tumor
Volume
Oncolytic
Virus
Dendritic Cells Rest Day
Rank 1 2 3 4 5 6 (mm3) dose number dose number count
1 D V - - - V 12.9 2 1 3
2 D V - V - V 14.5 3 1 2
3 D V V - V V 14.6 4 1 1
4 D V V - - V 15.1 3 1 2
5 D V - - V V 15.4 3 1 2
6 D V V V V V 18 5 1 0
7 D V - V V V 18.2 4 1 1
8 D V V V - V 19.3 4 1 1
9 V D V - V V 20 4 1 1
10 V D V - - V 20.6 3 1 2
11 V D - V - V 21 3 1 2
12 D V - - V - 23 2 1 3
13 D V D V - V 23.2 3 2 1
14 V D D V - V 24 3 2 1
15 V D V V V V 24.1 5 1 0
16 D V - V V - 24.8 3 1 2
17 V D V V - V 25.3 4 1 1
18 V D V D - V 25.6 3 2 1
19 V D V - D V 26.1 3 2 1
20 D V V - V - 26.5 3 1 2
Table 4.8: Permutation table representing flexible count, limited dose, lower dose
dendritic cell vaccines, while allowing for rest days. 20 permutations of the 729 are
displayed, that predict the tumor size at day 30. Injection quantities: Vmax = 1.5×1011,
Dmax = 3× 105, where the dosages were fractioned over 6 days.
Table [4.8] includes 729 permutations of OV and DC with maximum total dosage
of Vmax = 1.5× 1011 and DmaxL = 3× 105, including rest days. Evidently, lowering
DmaxL in combination with OV actually reduces overall tumor size. In contrast with
Table [4.6], the top 8 out of the top 20 of the 729 permutations start with DC and end
with OV. These results could suggest that starting with dendritic vaccination keeps
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these cells at bay, and await for the signal from the OV to deploy. At one order of
magnitude lower than used in the experimental work by Zhang et al. (2011), dendritic
cells allow the immune population to attack, but not wipe out all infected cells needed
for viral reproduction. We can also see that as the order of magnitude decreased by 1,
it also seems optimal to use the entire DmaxL all in one go, as opposed to dispersing
fractioned out dendritic treatments.
In Table [4.8], Dmax has at least one rest day. This could allow the system to
replenish the overall health of the subject via time for cell growth from cytotoxicity.
The (OV Count)total >(DC Count)total. Consistent with the limited maximum dose
function in Table [4.6], the OV seems to be carrying the weight of the combination
treatment, where the top 7 of 20 were only OV. With lower dosed dendritic treatment,
the OV combines with at least one DC for the top 12 of 20 in Table [4.8].
As we approach smaller tumor size, Table 4.7 compared regimens that made the
top 20 in Table [4.6] and Table [4.8].
Table Day Tumor Volume Oncolytic Virus Dendritic Cells Rest
4.6, 4.8 1 2 3 4 5 6 (mm3) dose number dose number Days
Permutation
Rank
Dmax, DmaxL
11,5 D V - - V V 39.9, 15.4 3,3 1,1 2,2
Table 4.9: Same sequence; Dmax compared to DmaxL . Total tumor size at day 30
Table 4.9 compared the same 6 day sequence with bounded maximum dose,
rest days allowed. Reducing the order of magnitude by one, during this sequence,
subsequently reduced the tumor size from 39.9 mm3 to 15.4 mm3, shown in Figure
4.11.
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Figure 4.11: Top results from Table 4.8
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Figure 4.12: Effects from changes of dendritic cell concentration on infected cancer cells,
directly and indirectly, over a 30 period. Dmax = [3×104, 3×105, 3×106]. a) Adaptive
immune response from dendritic cells to T cells for varying maximum tolerated dose.
b) T cell population change on Infected cells. c) Dendritic cell population change on
Infected cells.
According to regimen D V- - V V, Figure 4.12 represents phase plane diagrams
showing the effects from changes the dendritic cell concentration makes on infected cell
populations. DCs have no direct lytic activity on infected caner cells, since dendritic
cells have to activate T cells, which then respond to infected cells. Figure4.12a shows
the adaptive immune response from dendritic cells to T cells for varying maximum
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tolerated dose values overall 30 period. Figure 4.12b shows the effect of T cells on the
infected cancer population at varying maximum tolerated dose values, which occur at
a 30 day simulation. The end time in this figure is 6 days, in order to clearly show
the trajectories without overlapping lines. We can then see that for high populations
of dendritic cells, most of the infected cancer cells have a small population, in green,
a peak population at approximately 1.5 × 105 infected cancer cells. The reduced
dendritic vaccine count, shows higher infected cancer populations. Figure4.12c shows
a similar correlation, only from dendritic to infected cancer cells.
Higher peaks of infected cells occurred from lowering the dendritic vaccine dose,
seen in Figures 4.12b. More infected cells, could become viral which then reinfects
uninfected cancer cells. Therefore, it is best to monitor the intensity of the dendritic
vaccine dose. Similarly, this can be shown through the variation of the dendritic
activation rate, ρ, in Figure 4.13.
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Figure 4.13: Changes in ρ: Effects from changes of dendritic cell concentration on
infected cancer cells from altering adaptive immune response rate, ρ = [0.1, 1, 10]. a)
Adaptive immune response from dendritic cells to T cells for varying ρ values. b)
T cell population change on Infected cells. c) Dendritic cell population change on
Infected cells.
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4.3.3 Metronomic Therapy
The model assumes that cancer cells do not develop a resistance to OV, such that
all cells are sensitive to treatment. It could be the case that maintaining a certain
quantity of cancer cells may keep the tumor from reaching a noticeable low threshold,
which could produce more cancer cells quickly. Or depending on age, high toxic dose
may not be the best option. Hahnfeldt et al. (2003) found that treatment administered
over long term at lower low doses, could be optimal to maintain tumor growth in the
long term, instead of eradicating nearly all cells in the short term. This strategy is
defined as metronomic treatment,as the administration of lower dose treatment over
extended period of time (Hahnfeldt et al. (2003) , Kuang et al. (2016)).
Table 4.10: Permutation table representing for flexible dosing. 20 permutations of
the 4096 are displayed, that predict the tumor size at day 30. Injection quantities:
Vmax = 1.5× 1011, Dmax = 3× 106, where the dosages were fractioned over 12 days
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Figure 4.14: Top results from Table 4.10. Tumor Volume size is listed at day 30.
73
Table 4.11: Permutation table representing flexible dosing and low DC vaccine dose.
20 permutations of the 4096 are displayed, that predict the tumor size at day 30.
Injection quantities: Vmax = 1.5 × 1011, Dmax = 3 × 105, where the dosages were
fractioned over 12 days
According to Table 4.15, all low dose treatments should end with virotherapy on
the last day. In 19 of the 20 of the 4096 permutations, treatments started with V and
ended with a sequence of at least 3 DDDV.This could suggest building a dendritic
army that will be activated once the oncolytic virotherapy is administered last.
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Figure 4.15: Top results from Table 4.15
The most optimal treatment within a 30 day time frame would be V V D V D
D D D D D D V at Vmax = 1.5 × 1011 and Dmax = 3 × 105. Each viral treatment
would administer 3.75 ×1010(VP)/dose and dendritic treatment would administer 3.75
×104(VP)/dose .
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Figure 4.16: Optimal dose used in Zhang et al. (2011) compared to OVIT model (4.1)
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Figure 4.16 compared the optimal dose and frequency used experimentally in
Zhang et al. (2011) against the optimal result of the OVIT model. We can conclude
that administering a fraction of the treatment over double the amount of time, leaves
the tumor burden low and size smaller.
4.3.4 Intermittent Therapy
Intermittent therapy consists of altering periods of on- and off- treatments, in
order to keep tumor size below a given threshold. As this therapy was implementing
in the metronomic case, once per day over twelve days, this section will look at each
regimen; 6 days or 12 a single treatment, intermittently distributed over months.
While monitoring the growth of a tumor, a period of on-treatment can be initiated
once the tumor reaches a defined size (Tmax). On-treatment periods correspond with a
six to twelve day treatment regime. A period of off-treatment follows a given treatment
regime, during which cancer growth is monitored. Once a tumor reaches Tmax, the
patient is put back on-treatment and receives another full treatment regime (Figure
4.17).
On-Treatment
Give patient 
treatment regime
Off-Treatment
Monitor cancer
growth
If tumor size > Tmax
Figure 4.17: Proposed Optimal Intermittent Therapy strategy
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Here, model (4.1) is applied to a scenario of intermittent therapy over a six month
period with Tmax = 700mm
3. Figure 4.18 and Table 4.12 shows results of sample
treatment regimes under intermittent therapy. The optimal treatment regimen is used
for a six day treatment allowing days off: (D V - - - V) with D dose size of 3× 105 on
the first day of the on-treatment period and V dose size of 7.5× 1010 on the second
and sixth days of the on-treatment period (Figure 4.18 a). This regime was found to
be optimal in Table 4.8. These results were compared to the optimal metronomics
strategy found in Table 4.15, a twelve day treatment of: (V V D V D D D D D D
D V) with D dose size of 7.5× 103 and V dose size of 1.875× 1010 on the respective
days of the on-treatment period (Figure 4.18 b). These two intermittent strategies are
summarized in Table 4.12.
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Figure 4.18: Intermittent therapy over six month period: Model (4.1) predictions
with Tmax = 700 mm
3 for treatment regimes a.) Six day treatment regime of (D V -
- - V)with D dose size of 3 × 105 and V dose size of 7.5 × 1010 and b.) Twelve day
metronomics treatment regime of (V V D V D D D D D D D V) with D dose size of
7.5× 103 and V dose size of 1.875× 1010.
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Table 4.12: Intermittent therapy over six month period, model (4.1) predictions with
Tmax = 700 mm
3
Using a metronomics treatment strategy for intermittent therapy has some clear
advantages over traditional approaches. The total number of on-treatment periods
of the metronomic 12 day-low dose regime is lower than the number of on-treatment
periods of the traditional 6 day-high dose regime. Therefore the total amount of
viral and dendritic injections over a six month period is reduced using a metronomic
strategy (see Table 4.12).
4.4 Discussion
Oncolytic viruses enhance the production of antigens that signal immune responses.
There is also the understanding that OVs disrupt the microenvironment, which can
allow opportunities for the immune system to penetrate the cancer cell barrier. More
specifically, it is becoming fashionable to compliment dendritic cell vaccines with
oncolytic viruses.
For a variety of cancer types, oncologists have repertoires of treatment options.
However, for nearly all cancers, the optimal dose quantity, frequency and synergy
with potentially combining treatments, seems to invariably be of concern. Recent
pre-clinical and clinical studies suggest using oncolytic virotherapy as a means of
cancer treatment. Oncolytic virotherapy alone are not as effective as a monotherapy,
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as there is much focus on the safety components as there is to the cytotoxic traits.
Recent work showed combination therapy of OV and dendrites cell vaccines is better
than one or more alone (Zhang et al. (2011)). The work in this dissertation also has
shown the outcomes with smallest tumor volume are due to combination oncolytic viral
and immunotherapy. Summary table 4.13 includes a chart showing all the treatment
strategies for scheduling, dosing and timing against the end tumor volume for 30 days.
Table 4.13: Summary of all optimal treatment strategies
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4.4.1 Results Summary
Section 4.3.1 Altered experiments optimal with maintaining 3 doses of each, as
was done in previous experimental work for combination OV and DCs (Huang et al.
(2010), Zhang et al. (2011)).
Assuming that combination treatment using exactly half DCs and OVs, results
show from permutations of 20 results, altering treatments starting with dendritic cells
did the best Note, the optimal treatment used in experimental work of Zhang et al.
(2011), (VVVDDD), ranked 20 out of 20.
Section 4.3.1 allowed 6 treatments, with flexible frequency on the quantity of each
treatment, with a maximum of one treatment type per day. The treatment regimen
that reduced the tumor size over 30 days 6 full days of OV. This option, however, may
not be optimal since its total dose was doubled of that used in experimental work over
this time frame. Potential cytotoxic effects are a concern. Note, the optimal treatment
used in experimental work of Zhang et al. (2011), (VVVDDD), ranked 55 of 64.
Section 4.3.1 used exactly 3 and 3 of each type of therapy, which innately limited
the maximum permitted dose, given each OV dose was 5×1010 and DC 1×106. Section
4.3.1 allowed for a flexible count of each therapy over 6 days, which leads to altered
total dose ranges per treatment. Although the best was 6 days of OV, this result could
be a disservice to an individual who has a toxic reaction over a short amount of time.
Introducing the maximum tolerated dose (MTD) can provide an upper cytotoxic bound.
Section 4.3.2 allows for flexibility in the timing and count per treatment, but
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assume a limitation for the maximum tolerated dose. Results show combination
therapy is best, specifically when starting with DC. Nineteen of the top 20 of the 64
permutations started with DCs. The best treatment was DVVVVD. Note, the optimal
treatment used in experimental work of Zhang et al. (2011), (VVVDDD), ranked 61
of 64.
Many cancer treatments allow for rest days for the body to recover. The incor-
poration of rest days, in Section 4.3.2, showed the top 7 of the top 20 of the 729
permutations included only virus. There was a minimum of 3 treatments of V for
these top 7. Comparing the best treatment of V-V- - V with rest days to V D V D D
V without rest days, the observation was made that the treatment regimen without
DC did better than with. After various hypotheses, the conclusion came that DC
were too high. If the DC is too high, they will kill off the infected population, needed
to lyse into OV to kill uninfected cancer. The next hypothesis was lowering DC would
improve the reduction of tumor volume.
Section 4.3.2 explored rest days with DmaxL . Permutations of DC from (3× 100 −
3× 106) were made to find the most optimal DC count, fixing Vmax = 1.5× 1011. We
found 1× 105 was the optimal order of magnitude for DCs. Similar to the results for
6 days with rest days, in Table 4.8, OV count was greater than every DC count per
treatment. This observation is similar but not exact because 4.6 included OV greater
than or equal to the DC count. Simulations show that for one order of magnitude
of reduced DC treatment, there is enough infected cancer cells not attacked from
the immune system, via T cells, to re-infect more cancer cells. Following the same
immune trajectory, altered values were checked for the dendritic activation T cell rate,
ρ, shown in Figure 4.13. For ρ high, DmaxL , there are more T cells, which allow more
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infected cancer cells to be annihilated. With less infected cancer cells, there are less viri-
ons to infect uninfected cancer cells, which leads to an increase in overall tumor volume.
Section 4.3.2 allowed for a flexible schedule and maximum tolerated dose. Under
conditions where less dose per day is favorable to a patient, for purposes such as
species, age, health conditions, etc, the metronomic treatment idea was implemented
in Section 4.3.3 as part of the regimen schedule for model (4.1), to use less dose per day
over a longer period of time. Table 4.10 showed the top 20 of the 4096 permutations
calculated for tumor size at day 30. The range for the top 20 was [1.9-3.4] mm3;
x¯ = 2.93 mm3,thus, it seems they all produce significantly smaller tumors than of
the previous treatment experimented throughout Sections (4.3.1-4.3.2). 85% of the
top 20 regimens in Table 4.10 started with DCs followed mostly by OVs, where the
ratio of DCs:OVs is 1:3.21. These regimens, however, allowed for Dmax = 3 × 106.
As learned from Section 4.3.2 tumor size was smaller when the dendritic maximum
tolerated dose decreased, therefore this idea was also applied into lower dose over a
longer time frame for treatment, with metronomic. Table 4.11 shows the top 20 of
the 4096 permutations for lower dose DCs. The range for tumor size over 30 days
was [1.6-2.45];x¯ = 2.1 mm3. This range is the most optimal from all of this works
findings. The difference is there are more DCs on average than of OVs, contrary
to metronomic with Dmax = 3 × 106, with a ratio of OVs:DCs is 1:1.5, where 95%
of the regimens start with OV and 20 out of 20 end with OV, as well. The model
is built such that infected population declines quickly due to the high magnitude
of κy yz
K
. There is an interface competitive effect, allowing for κxyz
K
to represent a
stronger benefit from the immune system to the uninfected cancer population. The
metronomic treatment allows for at least a constant population of infected cells, y,
which reduces both uninfected and infected cancer cells. The non-metronomic case,
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under higher dosages in short amount of time, allowed for the reduction of infected
cells, without having the ability to be regrown. Thus, this interference competition
can allow the higher portion of uninfected cancer cells to take advantage of the
CTL cells more than the infected cancer cells. Moreso, the infected cancer cells are
not being depleted by the facilitation rate as much as the uninfected population, al-
lowing for further regeneration of free viral particles to reinfects the unfitted cancer cells
These results could support sigmoidal growth models that suggest treatments
administered closer in time results in higher cell kill, which deprives the regrowth
of cancer cells between treatment (Kuang et al. (2016)). More specifically, keeping
compact treatment schedules over a longer period of time, as in the case of using
metronomic treatment strategies used in Section 4.3.3.
4.4.2 Overall impact
To summarize, the initial research questions and results for this chapter were:
1)Are there better treatment regimens that reduce overall tumor size by day 30? Yes,
with MTD with Rest days and limited DC. 2)Can metronomic treatment further
reduce overall tumor size by day 30? Yes, with Metronomic therapy with limited
DC. 3)How do the effects of intermittent combination oncolytic viraltherapy and
immunotherapy reduce overall tumor size over time? Options for six day treatment or
twelve day treatment can be used as one single treatment option, intermittently over
time. Depending on the personal scenario, either could be used accordingly to reduce
overall tumor size, depending on a maximum tolerated tumor volume and cytotoxicity.
This model has expressed that timing, order and dose is sensitive to overall tumor
volume, over 30 days and up to 6 months. The timing at which either immunotherapy
or viraltherapy could be of clinical relevance. The time at which dendritic cells are
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injected seems to have relevance to the effectiveness of the combination, once OVT
is administered. It seems that DC prior to OV allows the DC’s to prime the area
of infection and can attack once OVT is administered. If DC are inject for the first
few days of treatment, they have no where to go, as their population is building up
and waits for the OV. During this time, the tumor can grow exponentially. This
could be an issue under circumstances where the tumor must be depressed within the
initial stages. Otherwise, it could be beneficial as a synergistic approach to prime the
OV effectiveness. Furthermore, reducing the order of magnitude for the DCs allowed
for improved effectiveness of OV, as 3× 106, was ultimately killing off the infected
cancer cells too quickly, inhibiting the re-infectivity of the OV genome. This result can
suggest that under combination treatment, it is important to monitor the quantity of
immunotherapy, such that too much can interfere the the benefits of the viraltherapy
if these infected cells are destroy by the immune system too quickly. According to
the model, maximum infectivity of oncolytic virotherapy is needed in order for OVT
treatment to be successful, which can be obtain with a light boost of DC’s prior or
in between treatments. The results of this work to find optimal treatment schedule,
supports that of Metronomic Therapy (Hahnfeldt et al. (2003)). The key reason the
metronomic treatment is ch the best in this work, is due to the constant influx of OV to
the infected cell population. In shorter days, such as the cases of 6 day treatment, the
infected cell populations would die off rather quickly, which dampens the potential for
further growth of the OV, independent of external injection. Including less dose over
a longer time frame, even at a lower dose, allows for a constant population of infected
cells to maintain the free viral population, which can persist to infect more cancer
cells. Model (4.1) under metronomic treatment, will be considered the “Metronomic
Oncolytic Viral-Immunotherapy”, or “MOVIT” model.
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Chapter 5
CONCLUSION
The research goals for this work were: 1) Develop a mathematical model that can
represent clinical variations for administering oncolytic viral therapy. 2) Parameterize
models using empirical data 3) Shed light on the complex dynamics of combined
oncolytic viral and immunotherapy and 4) Identify optimal treatment strategies (dose
sizes, treatment schedules) for a proposed personalized medicine model.
Modeling biology through in silico experimentation can provide great insight on
deep dynamical, relevant concerns. Chapter 3 presented a framework model of dy-
namical interactions between oncolytic viruses, cancer and the immune response. The
mathematical analysis provided insight on understanding which type of biological
conditions are necessary for drastic changes to occur in the system. It is important
to have mathematical analysis, but it may be difficult to plausibly apply the details
biologically. An important condition found for the threshold of oncolytic infection on
cancer, was the sensitivity of viral replication rate, β, shown with the occurrence of
a Hopf bifurcation. Biologically, changes in the viral replication value could depend
on the route of administration or efficacy of the drug. Most OVs are administered
intratumorally to enhance viral efficacy, and decrease chance of viral spread outside the
target region. In other cases, many OVs are coated with temporal protection against
the immune response in order to allow for viral replication. Mathematically, the viral
replication value could change depending on mass action or standard incidence, both
used in this work. In general, the mathematical analysis provides great insight on
conditions that occur clinically, and on which parameters play key roles on improving
questions of biological dynamics.
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The idea of curing cancer seems optimistic, yet perhaps, slightly unrealistic. Treat-
ing cancer to maintain a lower, tolerable level may be a more practical goal for
clinicians and could ameliorate effects and responses for patient viability. Chapter 4
explored optimal regimens that reduce tumor size, while attempting to account for
qualify of life conditions for a patient. Numerical analysis was a great tool enriching
the application of the model in various clinical dimensions. My foremost goal was
to fit the model to pre-clinical data. Although it is hoped that this work will be
applied clinically, the advantage of pre-clinical, non-human, data is its abundance. A
table of clinical trial regimens, Table 4.1 using oncolytic virotherapy, was constructed
to maintain a clinical-like direction for the model using pre-clinical data. Various
treatment strategies were then adapted into Model (4.1), accounting for dose quantity,
frequency and order of combination treatment administration. The key approach for
cancer treatment used in Chapter 4, was to reduce tumor growth and alleviate the
cancer burden of the patient, rather than indirectly kill them from drug toxicity. For
this, various permutations for schedule regimens of strategic concern were investigated.
Under assumptions made for Model (4.1), key results showed that keeping two
treatments at high concentrations while combined together, may not allow for their
maximal, synergistic benefits to reduce tumor size. Moreover, administering treat-
ments at fractionated doses over a longer time period, showed maximal reduction
in overall tumor size for a given time-span. Stronger doses in shorter time frames
did reduce tumor size quickly, but soon relapsed. Thus, metronomic oncolytic viral-
immunotherapy (MOVIT) could have clinical significance, whether in one treatment
as a sequence of doses, or intermittently as sequences of doses administered multiple
times. Overall, this work was able to show that timing and order of combination
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treatment is important for reducing overall tumor size, evaluate the synergistic effects
of combining treatments and develop a proposed scheme for personalize treatment
using intermittent therapy.
The following models are altered forms of Model (4.1).
Dynamics of Free Virus and Immune Response
We have seen in previous models (3.1)- (4.1) interactions between free viral popu-
lations lysed from oncolytic virus, infect cancer cells. The antigens presented from
the infection induce dendritic cells, that ultimately activated T killer cells that attack
uninfected and infected cells, respectively. As mention in the development of Model
(4.1), the tumor-microenvironment inhibits the immune system to attack cancer cells.
A trait of OVs is the ability to disrupt the tumor-microenvironment, which allows
access for the immune system to function near the tumor site. However,as the OV is
within the tumor during this time, and it is foreign, the immune system will unbiasedly
attack those free virions. With an decrease in OV population resulting from attacks
from the immune response , there will be a decline in free virions that can disrupt the
tumor micro-environment. This will subsequently close the time gap for the immune
system to attack the cancer cells, leading to an increase in tumor volume. Thus, it
is crucial to explore the dynamics between the interactions of OV and immune cells.
The below model is altered from (4.1).
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dx
dt
= rx− βxv
K
− f(y)xz
K
(5.1a)
dy
dt
= β
xv
K
− αy − f(y)yz
K
(5.1b)
dv
dt
= Nαy − δvv + uv(t)− g(x, v, z) (5.1c)
dD
dt
= σyy − δdD + ud(t) (5.1d)
dz
dt
= ρD − δzz (5.1e)
where term g(x, v, z) represents the immune attack on OVs free virions near the
site of the tumor microenvironment disruption. Also, f(y) denotes a function to
represent the mechanism of T killer cell facilitation depending on infected cancer cells.
OVIT model with Cancer-Immune Response
Model (4.1) assumed the tumor microenvironment was inhibiting the immune
system from attacking cancer cells. In the event the tumor microenvironent is disrupted
by the virus, or another factor, it would be useful to compare previous regimens from
Chapter 4 with allowing for a small, , immune response term. Thus, the uninflected
caner cell loss term -κy xz
K
− xz
K
, would not be completely dependent on the presence
of the infected cell, once initiated by the virus.
dx
dt
= rx− βxv
K
− (f(y)− )xz
K
(5.2a)
dy
dt
= β
xv
K
− αy − f(y)yz
K
(5.2b)
dv
dt
= Nαy − δvv + uv(t) (5.2c)
dD
dt
= σyy − δdD + ud(t) (5.2d)
dz
dt
= ρD − δzz (5.2e)
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OVIT model with Delayed Dendritic Cell Response
Dendritic cells function rather slowly in the immune system. Model (4.1) allows
for an immediate response from dendritic activation to T cells. Since the dendritic cell
vaccine was combined with oncolytic virotherapy, it would be of biological interest to
compare the regimens found in Chapter 4 with a delayed dendritic response. Allowing
a delay in this response time could permit the virus to persist and conquer some cancer
cells, reducing the uninfected cancer cell population. If the delay is too long, it could
be possible the response is out of clinical time for sufficient therapeutic conditions.
dx
dt
= rx− βxv
K
− f(y)xz
K
(5.3a)
dy
dt
= β
xv
K
− αy − f(y)yz
K
(5.3b)
dv
dt
= Nαy − δvv + uv(t) (5.3c)
dD
dt
= σyy − δdD + ud(t) (5.3d)
dz
dt
= ρD(t− τ)− δzz (5.3e)
ρD(t− τ) incorporated to represent the slow response from dendritic cells to T
killer cells where, the delay τ can be considered a discrete delay.
Future Direction
It is vital to understand how cancer interacts with non-conventional treatments,
in order to minimize tumor growth and maximize life. I feel in silico mathematical
model experimentation will play a crucial role in the clinical setting and can help gain
insight into clinical trials to pursue.
The era of using oncolytic viruses as a means of cancer treatment has just begun its
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horizon, clinically. Hopefully, an increase in pre-clinical and clinical experimentation
using oncolytic virotherapy will linearly produce abundant data sets. Certainly, the
data is irrelevant without good questions. Luckily, there are so many opportunities
of investigation within the unconventional usage of oncolytic viruses to treat cancer,
and unbounded permutations to unite the tools of mathematical modeling towards
improving cancer burden.
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Positive Invariance proof from 3.2.1
Proof. Suppose x+y = K → d(x+y)
dt
= rx
(
1− x+y
K
)−µx−β xv+β xv+sy (1− x+y
K
)−
αy − ρyz < 0. Logistic growth terms rx (1− x+y
K
) → 0 and sy (1− x+y
K
) → 0,
β xv − βxv = 0,
=⇒ d(x+y)
dt
= −µx− αy − ρyz < 0. It is trivial to show that dx
dt
, dy
dt
, dz
dt
&dv
dt
≥ 0.
∴ the system is positively invariant.
Proof for Theorem 1
The Generalized Jacobian matrix is:
J(E∗) =

r
(
1− x∗+y∗K
)
− rx∗K − µ− β v∗ − rx
∗
K 0 −β x∗
β v∗ − sy∗K s
(
1− x∗+y∗K
)
− sy∗K − α− ρz∗ −ρy∗ β x∗
0 z∗σ 0 0
0 Nα 0 −ξ

Proof. To prove that E0 is stable, it is sufficient to show that the system linearized at
this equilibrium has eigenvalues with real parts negative. This is represented in the
following Jacobian :
We look at the Jacobian to assess the stability of E0, represented as:
J(E0) =

r − µ 0 0 0
0 s− α 0 0
0 0 −φ 0
0 Nα 0 −ξ

From the diagonal matrix, the eigenvalues λ1 = −ξ, λ2 = −(µ − r), λ3 = −φ and
λ4 = −(α − s) are deduced. Whenever, λ1, λ2, λ3, λ4 < 0, the equilibria is locally
asymptotically stable. Thus, whenever r < µ, and s < α, E0 is L.A.S. Otherwise E0
is unstable.
Proof for Theorem 2
Proof. The Jacobian to asses the stability of E1, represented as:
J(E1) =

−(r − µ) −(r − µ) 0 −βK(r−µ)
r
0 −αr−µs
r
0 βK(r−µ)
r
0 0 −φ 0
0 Nα 0 −ξ

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From the matrix, the eigenvalues λ1 = −(r − µ), λ2 = −φ, and the other eigenvalues
can be funded by the solution of the next quadratic form
λ2 + a1λ+ a0
with a1 = [ξ +
αr−µs
r
] and a0 = [ξ
αr−µs
r
− βNαK(r−µ)
r
] = ξ αr−µs
r
(1−R0), for all r > µ.
In case of αr− µs > 0 the roots of the quadratic equation are negative if and only
if R0 < 1 and also it is easy to see that if R0 ≥ 1 E1 is unstable.
In case of in case of αr − µs < 0 it is clear to see that a0 < 0; then E1 is
unstable. Moreover, it is easy to prove that a21 − 4a0 > 0 in both cases. Thus E1, is
locally-asymptotically stable if and only if R0 < 1 and α > s for all r > µ.
Note that R0 < 1 if and only if µ < r <
NβKα− sξ
NβKα− αξµ
Proof for Theorem 3
Proof. The Jacobian to assess the stability of E1, represented as:
J(E2) =

rα
s
− µ− (s− α)βNαK
sξ
0 0 0
βNKα(s−α)
sξ
− (s− α) −(s− α) −pK(s−α)
s
0
0 0 σK(s−α)
s
− φ 0
0 Nα 0 −ξ

From the matrix, the eigenvalues λ1 = −(s− α), λ2 = −ξ, λ3 = −( φsK(s−α) − σ) and
λ4 = r
α
s
− µ− (s− α)βNα
sξ
. Thus, λ3 < 0 if and only if σ <
φs
K(s−α) also λ4 < 0 if and
only if r < µ.
Proof for Theorem 4
Proof. The Jacobian to asses the stability of E3, represented as:
J(E3) =

r(1− y
K
)− µ− β v 0 0 0
β v − sy
K
s
(
1− y
K
)− sy
K
− α− pz −py 0
0 zσ 0 0
0 Nα 0 −ξ

From the matrix, the eigenvalues are λ1 = −{ KK−φ
σ
(µ+ βNαφ
σξ
)− r}, λ2 = −ξ, and the
other eigenvalues can be funded by the solutions of the next quadratic form
λ2 + b1λ+ b0
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with b1 =
sφ
σK
and b0 = φ(s
K−φ
σ
K
− α). Since b1 > 0 and b0 > 0 for all σ > φsK(s−α) Thus,
E3 is stable if and only if σ >
φs
K(s−α) and σ >
βNKαb+rbξ
Kξ(r−µ) , otherwise E3 is unstable.
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Experimental Design
Mice with B16-F10 subcutaneous tumors were intratumorally infected with PBS,Ad−
∆B7, Ad−∆B7/IL− 12, Ad−∆B7/4− 1BBL and Ad−∆B7/IL− 12/4− 1BBL.
Each experiment contained n=8-9 mice.
This data set developed the following model that can capture the dual oncolytic
and immunotherapy aspects.
Model Formulation
dx
dt
= rx− βxv
K
− (γx + κy)xt
K
(B.1a)
dy
dt
= β
xv
K
− αyy − (γy + κy)yz
K
(B.1b)
dv
dt
= uv(t) +Nαy − δvv (B.1c)
dz
dt
= ρD − δzz (B.1d)
dD
dt
= σxx+ σyy − δdD + ud(t) (B.1e)
The model consists of x, y, v, z and D representing uninfected cancer cells, infected
cancer cells, virus free particles, T killer cells, and dendritic cells, respectively. This
model is an extension from Wares et al. (2015). Uninfected cells grow exponentially
at growth r, and are killed off by T killer cells at facilitation rate κy . The term
κy is dependent on infected cells, therefore, the assumption is that oncolytic viruses
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facilitate an immune response via the T killer cells towards the tumor. Uninfected
cancer cells are infected at rate β, as standard incidence, where K = x+ y + z +D.
Infected cells die at lysing rate α, T killer cells have an enhanced immune response at
rate γx and γy, for uninfected and infected cancer cells, respectively. This is due to the
OV immunogenicity trait. Viruses are grown from lysing rate α with burst size N , and
decay at δv. T killer cells are activated by dendritic cells at rate ρ and have a half life
at rate δz. Dendritic cells are recruited from the presence of tumor and infected tumor
populations at rates, σx and σy, respectively and decay at rate δD. Therapies are
introduced as delta functions for uv(t) and ud(t) for virotherapy and immunotherapy.
The model has fit to uv(t) = u0δ(0) + δ(2) + δ(4), and ud(t) = u0δ(1) + δ(3) + δ(5).
Parameter Fitting
Model (B.1) was fit to experimental data from Huang et al. (2010)
Parameter Description PBS DC Ad-∆B7
/4-1BBL
Ad-∆B7
/4-1BBL +DC
r Uninfected tumor cell growth rate 0.34484 0.34484 0.34484 0.34484
γx T cell contact rate, uninfected - 0.17206 0.17206 0.17206
γy T cell contact rate, infected - 0.17206 0.17206 0.17206
σx dendrite activation from unin-
fected cells
- 0.15113 0.15113 0.15113
σy dendrite activation from infected
cells
- - σx ∗ 1.1 σx ∗ 1.1
β Viral infectious rate - - 0.0053884 0.0058385
κ T cell killing rate - - 8.5× 10−7 8.5× 10−7
δz T cell decay rate - 0.35 0.35 0.35
δD Dendritic cell death rate - 0.35 0.35 0.35
ρ T cell activation rate by dendritic
cells
- 1 1 1
u0D Dendritic concentration - 10
6 - 106
u0V Adenovirus concentration - - 2.5 x 10
9 2.5 x 109
N adenovirus burst size - - 3500 3500
α Infected lysis - - 1 1
δV Viral decay rate - - 2.3 2.3
Table B.1: Parameter estimates for model (B.1)
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From the fits, one could confer that since there is no difference between γx and γy,
the model may not convey the T cell immune response independently. Furthermore,
it is suggested that OV activate immune response near the infected cells, such that
γx << γy, which does not seem to be captured in these fittings.
Additionally, σx is removed as the dendritic cell activation from the uninfected cells is
considered relatively small compared to infected cells, under common immune sup-
pressed conditions. Therefore, σy=σx ∗ 1.1 to attempt to account for a more abundant
immune response from the infected cell.
The model may could be improved to capture suggested dynamics of the immune
response by further simplifying it, by removing parameters that carry less weight
within the biology. Parameters γx and σx are removed in the model in Chapter 4, as
they seem to be considered biologically not as significant as the interactions from the
infected populations to the immune components.
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All tables presented in Chapter 4 included up to 20 permutations. This appendix
includes more data. However, data sets that include 729 - 4096 permutations were
capped at 60 permutations in this appendix.
Tables C.1-C.2 shows all 64 permutations for altering regimes, with flexible fre-
quencies.
108
Table (C.1) represents all possible 64 permutations of six treatments for the first
six days of therapy.
Permutation Day Tumor Volume Oncolytic Virus Dendritic Cells
Rank 1 2 3 4 5 6 (mm3) dose number dose number
1 V V V V V V 4.3 6 0
2 D V V V V V 6.4 5 1
3 V D V V V V 13.6 5 1
4 V V V V V D 14 5 1
5 D V V V V D 17.9 4 2
6 D D V V V V 22 4 2
7 V V D V V V 22.1 5 1
8 V V V V D V 22.8 5 1
9 D V V V D V 24 4 2
10 D V D V V V 25.2 4 2
11 D V V D V V 27.3 4 2
12 V V V D V V 29.2 5 1
13 V D V V V D 35 4 2
14 V D D V V V 35.7 4 2
15 V D V V D V 40 4 2
16 V D V D V V 40.9 4 2
17 D V V V D D 49 3 3
18 V V V V D D 49.6 4 2
19 D D D V V V 50.3 3 3
20 D D V D V V 53.1 3 3
21 V V D D V V 55.5 4 2
22 D D V V V D 55.9 3 3
23 D D V V D V 56.7 3 3
24 D V D D V V 58.4 3 3
25 V V D V V D 58.5 4 2
26 V V D V D V 61.3 4 2
27 D V D V D V 62.3 3 3
28 D V D V V D 62.7 3 3
29 D V V D D V 64.6 3 3
30 D V V D V D 65.9 3 3
31 V D D D V V 77.4 3 3
32 V V V D D V 86.1 4 2
33 V D D V D V 86.7 3 3
34 V V V D V D 87 4 2
35 V D D V V D 94.2 3 3
36 V D V V D D 98.6 3 3
37 V D V D D V 101.2 3 3
38 V D V D V D 113.6 3 3
39 D D D V D V 123.6 2 4
40 D D D D V V 124 2 4
41 D D V D D V 130.5 2 4
42 D V D D D V 143.7 2 4
43 V V D D D V 146.3 3 3
44 D D D V V D 153 2 4
45 D D V D V D 159.5 2 4
46 D D V V D D 167.7 2 4
47 D V D D V D 179.1 2 4
48 V V D D V D 181.9 3 3
49 D V V D D D 188.8 2 4
50 D V D V D D 189 2 4
51 V V D V D D 209.3 3 3
52 V D D D D V 224.1 2 4
53 V D D D V D 301.1 2 4
54 V D D V D D 385.9 2 4
55 V V V D D D 630.7 3 3
56 V D V D D D 640 2 4
57 D D D D D V 1594.3 1 5
58 D D D D V D 1639.7 1 5
59 D D D V D D 1755.6 1 5
60 D D V D D D 2203.7 1 5
61 D V D D D D 5171.3 1 5
62 V V D D D D 29485 2 4
63 V D D D D D 715180 1 5
64 D D D D D D 11861000 0 6
Table C.1: Permutation table representing flexible count for oncolytic viruses and
dendritic cell vaccines, over 6 days. All 64 are displayed, predicting the tumor size at
day 30. Each injection included V=5× 1010, D=1× 106.
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Table (4.5) shows the 64 permutations for administering combination treatment
without limitations on frequency per treatment, however the max dosage concentration
is limited to the amount used in the experiment from Zhang et al. (2011).
Permutation Day Tumor Volume Oncolytic Virus Dendritic Cells
Rank 1 2 3 4 5 6 (mm3) dose number dose number
1 D V V V V D 42.9 4 2
2 V V V V V V 44.1 6 0
3 D V V V D D 49 3 3
4 D D D V V V 50.3 3 3
5 D D V V V V 50.3 4 2
6 D V V V V V 51.9 5 1
7 D D V D V V 53.1 3 3
8 D V V V D V 54.2 4 2
9 D D V V V D 55.9 3 3
10 D D D D V V 56.2 2 4
11 D V D V V V 56.5 4 2
12 D D V V D V 56.7 3 3
13 D D D V D V 57.6 2 4
14 D V D D V V 58.4 3 3
15 D V V D V V 59.7 4 2
16 D D V D D V 61 2 4
17 D V D V D V 62.3 3 3
18 D V D V V D 62.7 3 3
19 D V V D D V 64.6 3 3
20 D V V D V D 65.9 3 3
21 D V D D D V 67.9 2 4
22 D D D V V D 68.8 2 4
23 V D V V V D 70.7 4 2
24 V D V V V V 73 5 1
25 D D V V D D 73.3 2 4
26 D D V D V D 73.3 2 4
27 V D D V V V 73.4 4 2
28 D V V D D D 75.2 2 4
29 V D D D V V 77.4 3 3
30 V D V V D V 81.3 4 2
31 V D V D V V 83.5 4 2
32 D V D D V D 83.8 2 4
33 D V D V D D 86.5 2 4
34 V D D V D V 86.7 3 3
35 V D D D D V 92.3 2 4
36 V D D V V D 94.2 3 3
37 V V V V V D 97.9 5 1
38 V D V V D D 98.6 3 3
39 V D V D D V 101.2 3 3
40 V V D V V V 106.6 5 1
41 V D V D V D 113.6 3 3
42 V V D D V V 114.7 4 2
43 D D D D D V 121.9 1 5
44 V D D D V D 123 2 4
45 V V D V V D 123.8 4 2
46 V V D V D V 132.2 4 2
47 V V D D D V 146.3 3 3
48 D D D D V D 148.5 1 5
49 V D D V D D 151.8 2 4
50 V V V D V V 156.3 5 1
51 D D D V D D 168.1 1 5
52 V V D D V D 181.9 3 3
53 D D V D D D 196.5 1 5
54 V V V D D V 201 4 2
55 V V V D V D 208.4 4 2
56 V V D V D D 209.3 3 3
57 V D V D D D 212.3 2 4
58 V V V V D D 216 4 2
59 V V V V D V 245.5 5 1
60 D V D D D D 315.5 1 5
61 V V V D D D 630.7 3 3
62 V V D D D D 2063.2 2 4
63 V D D D D D 4154.4 1 5
64 D D D D D D 11900000 0 6
Table C.2: Permutation table of limited maximum doses for oncolytic viruses and
dendritic cell vaccines. All permutations of the 64 are displayed, that predict the
tumor size at day 30. Vmax = 1.5 × 1011, Dmax = 3 × 106, where the dosages were
fractioned over 6 days.
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Tables C.3-C.4 show 60 of the 729 permutations for altering regimes with flexible
frequencies, rest days included.
Permutation Day Tumor Volume Oncolytic Virus Dendritic Cells Rest Day
Rank 1 2 3 4 5 6 (mm3) dose number dose number count
1 V - V - - V 26.6 3 0 3
2 V V - V - V 27.7 4 0 2
3 V V V - - V 29.7 4 0 2
4 V V V - V V 33.8 5 0 1
5 V V - - - V 34.1 3 0 3
6 V V V V - V 37 5 0 1
7 V - V V - V 37.8 4 0 2
8 D V - V V D 37.9 3 2 1
9 D - V - V V 39.5 3 1 2
10 D - - V - V 39.6 2 1 3
11 D V - - V V 39.9 3 1 2
12 D - V - - V 40.1 2 1 3
13 D - - V V V 40.3 3 1 2
14 V V - - V V 40.5 4 0 2
15 D - V V V D 40.9 3 2 1
16 D V - - - V 41.3 2 1 3
17 D - V - V D 41.5 2 2 2
18 V V - V V V 41.5 5 0 1
19 D - - - V V 41.8 2 1 3
20 D V - - V D 41.8 2 2 2
21 D V V V V D 42.9 4 2 0
22 V V V V V V 44.1 6 0 0
23 D D - V - V 44.4 2 2 2
24 D D V - V V 44.5 3 2 1
25 V - - V - V 44.6 3 0 3
26 D V - V V V 44.8 4 1 1
27 D - V V V V 44.9 4 1 1
28 D D - V V V 45.1 3 2 1
29 D D V - - V 45.4 2 2 2
30 D D - - V V 45.9 2 2 2
31 D V V - V D 46.7 3 2 1
32 D - V V - V 47.6 3 1 2
33 D V - V - V 48.1 3 1 2
34 D V - V D D 48.7 2 3 1
35 D V V - V V 48.8 4 1 1
36 D V V V D D 49 3 3 0
37 - D - V - V 49.2 2 1 3
38 V - V - V V 49.4 4 0 2
39 - D V - V V 49.7 3 1 2
40 D D D V - V 49.8 2 3 1
41 - D - V V V 49.8 3 1 2
42 D - D V - V 50 2 2 2
43 - D - - V V 50.1 2 1 3
44 D D D V V V 50.3 3 3 0
45 D D V V V V 50.3 4 2 0
46 D V - V D V 50.3 3 2 1
47 D - D V V V 50.5 3 2 1
48 D D D - V V 50.7 2 3 1
49 D - - V V D 50.8 2 2 2
50 - D V - - V 50.8 2 1 3
51 D V D - V V 51 3 2 1
52 D - D - V V 51 2 2 2
53 - D V - V D 51.9 2 2 2
54 D V V V V V 51.9 5 1 0
55 V - V - V - 52.4 3 0 3
56 - D V V V D 52.5 3 2 1
57 D V D - - V 52.6 2 2 2
58 D D V D V V 53.1 3 3 0
59 D D V V - V 53.3 3 2 1
60 D V - D V V 53.9 3 2 1
Table C.3: Limited Dose with Rest days at Dmax = 3×106. Top 60 of 729 Permutations.
Tumor size predicted at day 30. Vmax = 1.5× 1011, Dmax = 3× 106, where the dosages
were fractioned over 6 days.
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Permutation Day Tumor Volume Oncolytic Virus Dendritic Cells Rest Day
Rank 1 2 3 4 5 6 (mm3) dose number dose number count
1 D V - - - V 12.9 2 1 3
2 D V - V - V 14.5 3 1 2
3 D V V - V V 14.6 4 1 1
4 D V V - - V 15.1 3 1 2
5 D V - - V V 15.4 3 1 2
6 D V V V V V 18 5 1 0
7 D V - V V V 18.2 4 1 1
8 D V V V - V 19.3 4 1 1
9 V D V - V V 20 4 1 1
10 V D V - - V 20.6 3 1 2
11 V D - V - V 21 3 1 2
12 D V - - V - 23 2 1 3
13 D V D V - V 23.2 3 2 1
14 V D D V - V 24 3 2 1
15 V D V V V V 24.1 5 1 0
16 D V - V V - 24.8 3 1 2
17 V D V V - V 25.3 4 1 1
18 V D V D - V 25.6 3 2 1
19 V D V - D V 26.1 3 2 1
20 D V V - V - 26.5 3 1 2
21 V - V - - V 26.6 3 0 3
22 V D - V V V 27 4 1 1
23 V V - V - V 27.7 4 0 2
24 V - D V - V 27.9 3 1 2
25 V D V D D V 28.4 3 3 0
26 V D D V D V 28.5 3 3 0
27 V D V D V V 28.8 4 2 0
28 V D - V D V 29 3 2 1
29 V V V - - V 29.7 4 0 2
30 D V V V V - 30.2 4 1 1
31 D V D V V V 30.5 4 2 0
32 D V V D - V 30.5 3 2 1
33 D V V D V V 32 4 2 0
34 V D D V V V 32.2 4 2 0
35 D V - V D V 32.6 3 2 1
36 D V V - D V 32.9 3 2 1
37 V V D - V V 33.4 4 1 1
38 V V V - V V 33.8 5 0 1
39 V V - - - V 34.1 3 0 3
40 V D - - V V 34.1 3 1 2
41 D - V V - V 34.2 3 1 2
42 V D V V D V 34.9 4 2 0
43 V V D V - V 35.1 4 1 1
44 D V D - V V 35.6 3 2 1
45 V V D V V V 35.7 5 1 0
46 D V D - - V 35.9 2 2 2
47 D V D V D V 35.9 3 3 0
48 V D V - V - 36 3 1 2
49 V D - - - V 36.1 2 1 3
50 V - V D - V 36.4 3 1 2
51 V - D V D V 36.8 3 2 1
52 V V D D V V 36.9 4 2 0
53 V V D - - V 37 3 1 2
54 V V V V - V 37 5 0 1
55 D D V V - V 37.4 3 2 1
56 V D V - V D 37.6 3 2 1
57 V - V V - V 37.8 4 0 2
58 D V V V D V 38.5 4 2 0
59 V - V D D V 38.6 3 2 1
60 V V D V D V 39.2 4 2 0
Table C.4: Limited Dose with Rest days at Dmax = 3×105. Top 60 of 729 Permutations.
Tumor size predicted at day 30. Vmax = 1.5× 1011, Dmax = 3× 105, where the dosages
were fractioned over 6 days.
Tables C.5-C.6 show the top 60 of the 4096 permutations for altering regimes, with
flexible frequencies under the metronomic treatment strategy.
112
Permutation Day End Tumor
Volume
Oncolytic
Virus
Dendritic
Cells
Rank 1 2 3 4 5 6 7 8 9 10 11 12 (mm3) dose number dose number
1 D V V V V V V V V V V D 1.9 10 2
2 D V V V V V V V V V V V 2.2 11 1
3 D V V V V V V V V V D D 2.2 9 3
4 D D V V V V V V V V V V 2.3 10 2
5 D D D V V V V V V V V V 2.6 9 3
6 D V D V V V V V V V V V 2.8 10 2
7 D D V D V V V V V V V V 2.9 9 3
8 D D D D V V V V V V V V 2.9 8 4
9 D D V V V V V V V V V D 2.9 9 3
10 D D D V D V V V V V V V 3.1 8 4
11 V D V V V V V V V V V D 3.1 10 2
12 V D V V V V V V V V V V 3.2 11 1
13 D V D D V V V V V V V V 3.2 9 3
14 D D V D D V V V V V V V 3.2 8 4
15 D V V V V V V V V D D D 3.3 8 4
16 D V V V V V V V V V D V 3.3 10 2
17 D D V V D V V V V V V V 3.3 9 3
18 D D D V V D V V V V V V 3.4 8 4
19 V D D V V V V V V V V V 3.4 10 2
20 D D D V D D V V V V V V 3.4 7 5
21 D V V D V V V V V V V V 3.5 10 2
22 D D D D V D V V V V V V 3.5 7 5
23 D V D D D V V V V V V V 3.5 8 4
24 D D V D D D V V V V V V 3.5 7 5
25 D V D V V V V V V V V D 3.5 9 3
26 D D V D V D V V V V V V 3.6 8 4
27 D V D V D V V V V V V V 3.6 9 3
28 D D D D D V V V V V V V 3.7 7 5
29 D D D D V V D V V V V V 3.7 7 5
30 D D D V D V D V V V V V 3.7 7 5
31 D D D V V V V V V V V D 3.7 8 4
32 V D D D V V V V V V V V 3.7 9 3
33 D V V V V V V V V D V D 3.7 9 3
34 D D V D D V D V V V V V 3.8 7 5
35 D V D D D D V V V V V V 3.8 7 5
36 D D D V V V D V V V V V 3.8 8 4
37 D V D D V D V V V V V V 3.8 8 4
38 D D V V V V V V V V D D 3.8 8 4
39 D D D V D D D V V V V V 3.8 6 6
40 D D V V V D V V V V V V 3.8 9 3
41 D D V D D D D V V V V V 3.8 6 6
42 V D V V V V V V V V D D 3.9 9 3
43 D D V V D D V V V V V V 3.9 8 4
44 D D D V D D V D V V V V 3.9 6 6
45 D D D V V D D V V V V V 3.9 7 5
46 D V V V V V V V V D D V 3.9 9 3
47 D D V D D D V D V V V V 3.9 6 6
48 D D V D V V D V V V V V 4 8 4
49 D V D D D V D V V V V V 4 7 5
50 D D V D V D D V V V V V 4 7 5
51 D D D D V D V D V V V V 4 6 6
52 D D D V D V V D V V V V 4 7 5
53 D D V D V V V V V V V D 4 8 4
54 D D D D V V V D V V V V 4 7 5
55 D V V D D V V V V V V V 4 9 3
56 D D D D V D D V V V V V 4 6 6
57 V D V D V V V V V V V V 4.1 10 2
58 V D D D D V V V V V V V 4.1 8 4
59 D D D V D V D D V V V V 4.1 6 6
60 V D D V D V V V V V V V 4.1 9 3
Table C.5: Permutation table representing for flexible dosing. 60 permutations of
the 4096 are displayed, that predict the tumor size at day 30. Injection quantities:
Vmax = 1.5× 1011, Dmax = 3× 106, where the dosages were fractioned over 12 days
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Permutation Day Tumor Vol-
ume
Oncolytic
Virus
Dendritic
Cells
Rank 1 2 3 4 5 6 7 8 9 10 11 12 (mm3) dose number dose number
1 V V D V D D D D D D D V 1.59 4 8
2 V V D D V D D D D D D V 1.61 4 8
3 V D V D V D D D D D D V 1.64 4 8
4 V D V D D V D D D D D V 1.74 4 8
5 V D V V D D D D D D D V 1.8 4 8
6 V V D D D V D D D D D V 1.97 4 8
7 D V V V V V V V V V V V 2.06 11 1
8 V V D V D D V D D D D V 2.17 5 7
9 V V V D D D D D D D D V 2.2 4 8
10 V V V D D V D D D D D V 2.19 5 7
11 V D V D D D D D D D D V 2.2 3 9
12 V V D V D V D D D D D V 2.2 5 7
13 V V V D V D D D D D D V 2.21 5 7
14 V V D V D D D V D D D V 2.23 5 7
15 V V V D D D V D D D D V 2.27 5 7
16 V V D V V D D D D D D V 2.3 5 7
17 V V V V D D D D D D D V 2.4 5 7
18 V D V V D V D D D D D V 2.41 5 7
19 V D V V D D V D D D D V 2.44 5 7
20 V D V D D D V D D D D V 2.5 4 8
21 V V D V D D D D V D D V 2.45 5 7
22 V D D V D V D D D D D V 2.5 4 8
23 V V V D V D D D D V D V 2.5 6 6
24 V V V D V D D D D D V V 2.5 6 6
25 V D V V V D D D D D D V 2.5 5 7
26 V V D D V D V D D D D V 2.56 5 7
27 V V V D V D D D V D D V 2.59 6 6
28 V V V D D D D V D D D V 2.59 5 7
29 V D D V D D D D D D D V 2.61 3 9
30 V V D D V V D D D D D V 2.61 5 7
31 V D V D V D V D D D D V 2.62 5 7
32 V V D V D D D D D D V D 2.62 4 8
33 V V V V D V D D D D V V 2.63 7 5
34 V D V V D D D V D D D V 2.64 5 7
35 V V D D V D D D D D V D 2.69 4 8
36 V D V D V V D D D D D V 2.69 5 7
37 V V D D V D D V D D D V 2.7 5 7
38 V D V D V D D V D D D V 2.73 5 7
39 V V V D V D D V D D D V 2.73 6 6
40 V D V D V D D D D D V D 2.75 4 8
41 V V V V D D D V D D D V 2.79 6 6
42 V V V V D D D D V D D V 2.79 6 6
43 V V V V D D V D D D D V 2.86 6 6
44 V V D V V D D D V D D V 2.88 6 6
45 V V V D V D V D D D D V 2.9 6 6
46 V V D V V D D D D V D V 2.92 6 6
47 V D V V D D D D D D V D 2.94 4 8
48 V D V D D V D D D D V D 2.94 4 8
49 V D V D D D D D D D V D 2.94 3 9
50 V D D V V D D D D D D V 2.94 4 8
51 V V D V V D D V D D D V 2.95 6 6
52 V V V V D D D D D V D V 2.97 6 6
53 V V V V D V D D D V D V 2.98 7 5
54 V V V V D V D D D D D V 2.98 6 6
55 V V D V D V D D D V D V 2.99 6 6
56 V V V V V D D D D D V V 2.99 7 5
57 V V D V D V D D V D D V 3.03 6 6
58 V V D V V D V D D D D V 3.08 6 6
59 V V V D V V D D D D D V 3.09 6 6
60 V V V D D V D D V D D V 3.13 6 6
Table C.6: Permutation table representing for flexible dosing. 60 permutations of
the 4096 are displayed, that predict the tumor size at day 30. Injection quantities:
Vmax = 1.5× 1011, Dmax = 3× 106, where the dosages were fractioned over 12 days
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